JPH08231370A - Skin cosmetic - Google Patents
Skin cosmeticInfo
- Publication number
- JPH08231370A JPH08231370A JP7062025A JP6202595A JPH08231370A JP H08231370 A JPH08231370 A JP H08231370A JP 7062025 A JP7062025 A JP 7062025A JP 6202595 A JP6202595 A JP 6202595A JP H08231370 A JPH08231370 A JP H08231370A
- Authority
- JP
- Japan
- Prior art keywords
- collagen synthesis
- placenta
- acid
- alcohol
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002537 cosmetic Substances 0.000 title claims abstract description 35
- 102000008186 Collagen Human genes 0.000 claims abstract description 112
- 108010035532 Collagen Proteins 0.000 claims abstract description 112
- 229920001436 collagen Polymers 0.000 claims abstract description 112
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 89
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 89
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 73
- 210000002826 placenta Anatomy 0.000 claims abstract description 45
- 239000002253 acid Substances 0.000 claims abstract description 26
- 241000283690 Bos taurus Species 0.000 claims abstract description 13
- 241000282414 Homo sapiens Species 0.000 claims abstract description 9
- 241000283707 Capra Species 0.000 claims abstract description 7
- 241001494479 Pecora Species 0.000 claims abstract description 4
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 230000001737 promoting effect Effects 0.000 abstract description 20
- 239000003795 chemical substances by application Substances 0.000 abstract description 9
- 239000000126 substance Substances 0.000 abstract description 8
- 230000004215 skin function Effects 0.000 abstract description 6
- 239000000654 additive Substances 0.000 abstract description 2
- 241000282898 Sus scrofa Species 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 36
- 239000000523 sample Substances 0.000 description 27
- -1 pH adjusters Substances 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 15
- 238000000034 method Methods 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- 210000004207 dermis Anatomy 0.000 description 9
- 210000002950 fibroblast Anatomy 0.000 description 8
- 238000001914 filtration Methods 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 235000014113 dietary fatty acids Nutrition 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000000194 fatty acid Substances 0.000 description 7
- 229930195729 fatty acid Natural products 0.000 description 7
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- 230000032683 aging Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000002500 effect on skin Effects 0.000 description 5
- 239000003205 fragrance Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000000967 suction filtration Methods 0.000 description 5
- 238000010998 test method Methods 0.000 description 5
- 238000000108 ultra-filtration Methods 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 235000021355 Stearic acid Nutrition 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 239000004359 castor oil Substances 0.000 description 4
- 235000019438 castor oil Nutrition 0.000 description 4
- 238000010908 decantation Methods 0.000 description 4
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 4
- 230000003169 placental effect Effects 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 239000008117 stearic acid Substances 0.000 description 4
- 230000037303 wrinkles Effects 0.000 description 4
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 239000004166 Lanolin Substances 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229920001214 Polysorbate 60 Polymers 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 108010009583 Transforming Growth Factors Proteins 0.000 description 3
- 102000009618 Transforming Growth Factors Human genes 0.000 description 3
- 239000003463 adsorbent Substances 0.000 description 3
- 229960000541 cetyl alcohol Drugs 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 229940075507 glyceryl monostearate Drugs 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 235000019388 lanolin Nutrition 0.000 description 3
- 229940039717 lanolin Drugs 0.000 description 3
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 230000036284 oxygen consumption Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000011085 pressure filtration Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 description 2
- ASKIVFGGGGIGKH-UHFFFAOYSA-N 2,3-dihydroxypropyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(O)CO ASKIVFGGGGIGKH-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 235000021357 Behenic acid Nutrition 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 239000006096 absorbing agent Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 229940116226 behenic acid Drugs 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- 235000014593 oils and fats Nutrition 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 229940055577 oleyl alcohol Drugs 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- DCBSHORRWZKAKO-UHFFFAOYSA-N rac-1-monomyristoylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OCC(O)CO DCBSHORRWZKAKO-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 2
- 229960001860 salicylate Drugs 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000009758 senescence Effects 0.000 description 2
- 229940035044 sorbitan monolaurate Drugs 0.000 description 2
- 239000001593 sorbitan monooleate Substances 0.000 description 2
- 229940035049 sorbitan monooleate Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- PDHSAQOQVUXZGQ-JKSUJKDBSA-N (2r,3s)-2-(3,4-dihydroxyphenyl)-3-methoxy-3,4-dihydro-2h-chromene-5,7-diol Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2OC)=CC=C(O)C(O)=C1 PDHSAQOQVUXZGQ-JKSUJKDBSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N 1-Tetradecanol Natural products CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- MEZZCSHVIGVWFI-UHFFFAOYSA-N 2,2'-Dihydroxy-4-methoxybenzophenone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1O MEZZCSHVIGVWFI-UHFFFAOYSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- LRZBIPQJHILPJI-UHFFFAOYSA-N 2,3-dihydroxypropyl 2-(2,3-dihydroxypropyl)octadecanoate Chemical compound CCCCCCCCCCCCCCCCC(CC(O)CO)C(=O)OCC(O)CO LRZBIPQJHILPJI-UHFFFAOYSA-N 0.000 description 1
- WHQOKFZWSDOTQP-UHFFFAOYSA-N 2,3-dihydroxypropyl 4-aminobenzoate Chemical compound NC1=CC=C(C(=O)OCC(O)CO)C=C1 WHQOKFZWSDOTQP-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- KNUPSOXBESCJLY-UHFFFAOYSA-N 2-methoxy-1-phenylhexan-1-one Chemical compound CCCCC(OC)C(=O)C1=CC=CC=C1 KNUPSOXBESCJLY-UHFFFAOYSA-N 0.000 description 1
- JYZLSYFPFQTNNO-UHFFFAOYSA-N 2-octyldecan-1-ol Chemical compound CCCCCCCCC(CO)CCCCCCCC JYZLSYFPFQTNNO-UHFFFAOYSA-N 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 description 1
- DBTMGCOVALSLOR-UHFFFAOYSA-N 32-alpha-galactosyl-3-alpha-galactosyl-galactose Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(OC2C(C(CO)OC(O)C2O)O)OC(CO)C1O DBTMGCOVALSLOR-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RXVWSYJTUUKTEA-UHFFFAOYSA-N D-maltotriose Natural products OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1OC1C(O)C(O)C(O)C(CO)O1 RXVWSYJTUUKTEA-UHFFFAOYSA-N 0.000 description 1
- UNXHWFMMPAWVPI-QWWZWVQMSA-N D-threitol Chemical compound OC[C@@H](O)[C@H](O)CO UNXHWFMMPAWVPI-QWWZWVQMSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical class C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- RJECHNNFRHZQKU-UHFFFAOYSA-N Oelsaeurecholesterylester Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCC=CCCCCCCCC)C2 RJECHNNFRHZQKU-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- PPWHTZKZQNXVAE-UHFFFAOYSA-N Tetracaine hydrochloride Chemical compound Cl.CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 PPWHTZKZQNXVAE-UHFFFAOYSA-N 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- NCHJGQKLPRTMAO-XWVZOOPGSA-N [(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NCHJGQKLPRTMAO-XWVZOOPGSA-N 0.000 description 1
- LDDUCKDUDZVHLN-UHFFFAOYSA-N [2-hydroxy-3-[2-hydroxy-3-(16-methylheptadecanoyloxy)propoxy]propyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(O)COCC(O)COC(=O)CCCCCCCCCCCCCCC(C)C LDDUCKDUDZVHLN-UHFFFAOYSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 239000010495 camellia oil Substances 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000004204 candelilla wax Substances 0.000 description 1
- 235000013868 candelilla wax Nutrition 0.000 description 1
- 229940073532 candelilla wax Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000012185 ceresin wax Substances 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- RJECHNNFRHZQKU-RMUVNZEASA-N cholesteryl oleate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)C1 RJECHNNFRHZQKU-RMUVNZEASA-N 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 229940071120 dehydroacetate Drugs 0.000 description 1
- 230000003544 deproteinization Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940105990 diglycerin Drugs 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- UVCJGUGAGLDPAA-UHFFFAOYSA-N ensulizole Chemical compound N1C2=CC(S(=O)(=O)O)=CC=C2N=C1C1=CC=CC=C1 UVCJGUGAGLDPAA-UHFFFAOYSA-N 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LFUPHQRGNKMSOY-UHFFFAOYSA-N ethyl 4-(3,3-dihydroxypropylamino)benzoate Chemical compound CCOC(=O)C1=CC=C(NCCC(O)O)C=C1 LFUPHQRGNKMSOY-UHFFFAOYSA-N 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 102000034240 fibrous proteins Human genes 0.000 description 1
- 108091005899 fibrous proteins Proteins 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000000054 fungal extract Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 239000008169 grapeseed oil Substances 0.000 description 1
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 1
- SFFVATKALSIZGN-UHFFFAOYSA-N hexadecan-7-ol Chemical compound CCCCCCCCCC(O)CCCCCC SFFVATKALSIZGN-UHFFFAOYSA-N 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- FYGDTMLNYKFZSV-UHFFFAOYSA-N mannotriose Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(O)C(O)C2O)CO)C(O)C1O FYGDTMLNYKFZSV-UHFFFAOYSA-N 0.000 description 1
- 229960003951 masoprocol Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- VAMXMNNIEUEQDV-UHFFFAOYSA-N methyl anthranilate Chemical compound COC(=O)C1=CC=CC=C1N VAMXMNNIEUEQDV-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 229940114937 microcrystalline wax Drugs 0.000 description 1
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- QTDSLDJPJJBBLE-PFONDFGASA-N octyl (z)-octadec-9-enoate Chemical compound CCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC QTDSLDJPJJBBLE-PFONDFGASA-N 0.000 description 1
- 229940073665 octyldodecyl myristate Drugs 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 1
- LXTZRIBXKVRLOA-UHFFFAOYSA-N padimate a Chemical compound CCCCCOC(=O)C1=CC=C(N(C)C)C=C1 LXTZRIBXKVRLOA-UHFFFAOYSA-N 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 239000001651 pyrus cydonia seed extract Substances 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 1
- 229960001755 resorcinol Drugs 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 229920002050 silicone resin Polymers 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940075554 sorbate Drugs 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- CXVGEDCSTKKODG-UHFFFAOYSA-N sulisobenzone Chemical compound C1=C(S(O)(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC=CC=C1 CXVGEDCSTKKODG-UHFFFAOYSA-N 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- ICUTUKXCWQYESQ-UHFFFAOYSA-N triclocarban Chemical compound C1=CC(Cl)=CC=C1NC(=O)NC1=CC=C(Cl)C(Cl)=C1 ICUTUKXCWQYESQ-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 239000006097 ultraviolet radiation absorber Substances 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- FYGDTMLNYKFZSV-BYLHFPJWSA-N β-1,4-galactotrioside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H](CO)O[C@@H](O[C@@H]2[C@@H](O[C@@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-BYLHFPJWSA-N 0.000 description 1
- 229930007845 β-thujaplicin Natural products 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
【０００１】[0001]
【産業上の利用分野】本発明は胎盤由来の成分を含有す
ることを特徴とするコラーゲン合成促進剤，その製造法
及びそれを含有することを特徴とする皮膚化粧料（医薬
部外品たる薬用化粧品を含む。以下同じ）に関する。FIELD OF THE INVENTION The present invention relates to a collagen synthesis promoter characterized by containing a placenta-derived component, a method for producing the same, and a skin cosmetic (containing quasi-drug medicinal product) characterized by containing the same. Including cosmetics. The same shall apply hereinafter).
【０００２】[0002]
【従来の技術】老齢化社会を迎えつつあるわが国におい
て、老化（エージング）に対する医学的関心が高まるな
か、皮膚科領域においても皮膚の老化メカニズム等に関
する研究が進められ、特に細胞賦活剤の投与による老化
制御に内外の注目が集まっている。従来、いくつかの動
植物及び菌類の抽出物に組織賦活能が認められ、医薬品
や化粧品に用いられてきた。しかしこれらのものの中
で、細胞レベルにおいて生理活性を有する物質として評
価されたものは少なく、例えば、組織切片に対するこれ
らの抽出物の添加による酸素の消費量の増加をワールブ
ルグ検圧計等を用いて測定する方法、また、ＡＴＰ等の
酸化的リン酸化を触媒するような酵素を用いた定量法が
試みられている。しかしながら、これらの手段では、例
えば、組織切片を用いた酸素消費量試験法によれば、水
も賦活能を有し、極端なことを言えば炭素や窒素源を持
った多くのものは適量の濃度にあって酸素の消費量の増
加を示す。少なくとも栄養剤としての評価にはこれらの
手段は有効であるが、細胞レベルで皮膚の機能を捉え検
体の評価を行うとき、これらの手段により細胞賦活能を
捉えることは無理な点が多かった。2. Description of the Related Art In Japan, which is facing an aging society, with increasing medical interest in aging, research on skin aging mechanism has been promoted in the field of dermatology. Aging control is attracting a lot of attention both inside and outside. Conventionally, some plant and animal extracts and fungal extracts have been found to have a tissue-activating ability, and have been used in pharmaceuticals and cosmetics. However, among these, few have been evaluated as substances having physiological activity at the cellular level, and for example, the increase in oxygen consumption due to the addition of these extracts to tissue sections was measured using a Warburg pressure gauge. In addition, a quantitative method using an enzyme that catalyzes oxidative phosphorylation of ATP and the like has been attempted. However, in these means, for example, according to the oxygen consumption test method using a tissue section, water also has an activating ability, and in extreme cases, many having a carbon or nitrogen source have an appropriate amount. It shows an increase in oxygen consumption depending on the concentration. At least, these means are effective for evaluation as a nutritional supplement, but when assessing the function of the skin at the cell level and evaluating the sample, it is often impossible to determine the cell activation ability by these means.
【０００３】皮膚は、組織化学的に大別すると、表皮，
真皮，皮下組織に分けられるが、特に真皮は皮膚の支持
組織として、皮膚の恒常性維持のために重要な役割を果
たしている。真皮の主な構成細胞は線維芽細胞であり、
コラーゲン等の蛋白質やヒアルロン酸などのグリコサミ
ノグリカンを産生し、これらの結合組織の中で構築構造
を形成している。コラーゲンはすべての多細胞動物にみ
られる特有な繊維蛋白質であり、皮膚真皮組織に存在す
る主要蛋白質である。コラーゲン分子は堅固な三本鎖ら
せん構造をした高分子化合物であり、長いコラーゲン分
子は皮膚真皮組織を強固にしてその形態を保ち、皮膚に
弾力性を与えていることから、生理的に皮膚の弾力性も
この物質にかかる機能と密接に結び付いていると考えら
れる。近年、老化に関する様々な研究が行われるように
なり、特に、コラーゲンが皮膚の機能に重要な役割をも
つことが解明されてきた。従来より、コラーゲンの皮膚
保湿効果などの優れた機能から、コラーゲンが種々の化
粧品に配合されているが、これら化粧品はコラーゲンを
皮膚表面に塗布するだけのものであり、コラーゲンは高
分子であるため表皮のバリアーに阻まれ吸収されないた
め、皮膚表面上にとどまり、その吸水性に起因する保湿
作用を示すのみである。従って、洗い落とせば効果が消
え、本質から皮膚機能を改善するものではなかった。The skin is roughly classified into histochemical epidermis,
The dermis is divided into the dermis and the subcutaneous tissue. Particularly, the dermis plays an important role in maintaining the homeostasis of the skin as a supporting tissue of the skin. The main constituent cells of the dermis are fibroblasts,
It produces proteins such as collagen and glycosaminoglycans such as hyaluronic acid, and forms a structured structure in these connective tissues. Collagen is a unique fibrous protein found in all multicellular animals and is a major protein present in cutaneous dermal tissue. Collagen molecules are high-molecular compounds with a solid triple-stranded helix structure, and long collagen molecules strengthen the dermal tissue of the dermis and maintain its shape, giving it elasticity to the skin, and thus physiologically Elasticity is also thought to be closely linked to the function of this substance. In recent years, various studies on aging have been conducted, and in particular, it has been clarified that collagen plays an important role in skin function. From the past, collagen has been blended in various cosmetics because of its excellent functions such as skin moisturizing effect, but these cosmetics only apply collagen to the skin surface, and collagen is a high molecule. Since it is not absorbed by the barrier of the epidermis and is not absorbed, it stays on the surface of the skin and only exhibits a moisturizing action due to its water absorption. Therefore, the effect disappears when washed off, and the skin function is not essentially improved.
【０００４】[0004]
【発明が解決しようとする問題点】皮膚機能に重要な役
割持つコラーゲンは、老化に伴い減少することが報告さ
れている。Shuster らは、ヒト正常皮膚中におけるコラ
ーゲン量を測定した結果、皮膚コラーゲン量は２０歳か
ら８０歳までの間に６５％減少し、真皮の厚さは薄くな
ることを示した（Brith Journal of Dermatology, 93,
639, 1975）。一方、Legrand らによると、コラーゲン
の代謝回転率も加齢により低下し、生体内に長時間存在
するため、コラーゲン繊維中に無秩序な架橋やメイラー
ド反応が進行し、非可溶性コラーゲンが増加し細胞外マ
トリックスの硬化の原因となる（Pathological Biolog
y, 17, 991, 1969）。これらの研究結果より、皮膚線維
芽細胞のコラーゲン合成を促進することができれば、真
皮のコラーゲン含量が増加し真皮の厚さを増し、それに
伴って代謝回転も活性化され、可溶性コラーゲンが増加
することにより皮膚に柔軟性，伸展性を与え、その結
果、皺に代表される老化皮膚の形態的変化を抑制できる
可能性がある。即ち、本発明は真皮の線維芽細胞のコラ
ーゲン合成を促進し、老化制御機能を有する胎盤由来の
コラーゲン合成促進剤及びその製造法及びそれを含有す
る新規皮膚化粧料を提供することを目的とする。[Problems to be Solved by the Invention] It has been reported that collagen, which plays an important role in skin function, decreases with aging. As a result of measuring the amount of collagen in normal human skin, Shuster et al. Showed that the amount of skin collagen was reduced by 65% between the ages of 20 and 80, and the thickness of the dermis was reduced (Brith Journal of Dermatology). , 93,
639, 1975). On the other hand, according to Legrand et al., The turnover rate of collagen also decreases with aging and stays in the body for a long time, which leads to disordered cross-linking and Maillard reaction in the collagen fiber, resulting in increased insoluble collagen and extracellular extracellular matrix. Causes matrix hardening (Pathological Biolog
y, 17, 991, 1969). From the results of these studies, if it is possible to promote the collagen synthesis of skin fibroblasts, the collagen content of the dermis increases, the dermis thickness increases, the turnover is also activated, and the soluble collagen increases. This may give the skin flexibility and extensibility, and as a result, it may be possible to suppress the morphological changes of aged skin represented by wrinkles. That is, an object of the present invention is to provide a placenta-derived collagen synthesis promoter having a function of controlling senescence, which promotes collagen synthesis of dermal fibroblasts, a method for producing the same, and a novel skin cosmetic containing the same. .
【０００５】[0005]
【問題を解決するための手段】本発明者らは、まず細胞
レベルで検体の評価を行うため、Peterkofsky らの方法
（Arch. Biochem. Biophys., 152, 318 ，1972）に準
じ、培養線維芽細胞を用いたコラーゲン合成能を試験し
た。即ち、本試験法は、細胞培養系に検体を添加後3Ｈ
ラベルしたプロリンを取り込ませることにより、細胞の
コラーゲン合成量を定量するものである。本発明者ら
は、動植物及び菌類より任意に選んだ種々の物質につい
て、そのコラーゲン合成促進作用を上述の試験法にてス
クリーニングした結果、胎盤の分画成分に高いコラーゲ
ン合成促進活性を認めるに至った。即ち、胎盤のコラー
ゲン合成促進作用成分は、胎盤の酸・アルコール可溶画
分に移行することが明らかとなり、コラーゲン合成促進
作用成分を豊富に含有する本発明のコラーゲン合成促進
剤を完成するにいたった。更に、本発明者らは本発明の
コラーゲン合成促進剤を配合した皮膚化粧品を調製し皮
膚に塗布したところ、皮膚機能を亢進し肌の皺を防止
し、きめ細かな、かつしっとりした皮膚にすることを発
見し、更にその高い安全性を確認したため、本発明の皮
膚化粧料を完成するにいたった。なお本発明のコラーゲ
ン合成促進剤を配合した皮膚化粧料は真皮線維芽細胞の
コラーゲン合成を促進することによりその効果を現すも
のと考えられた。[Means for Solving the Problem] In order to evaluate the sample at the cell level, the present inventors have followed the method of Peterkofsky et al. (Arch. Biochem. Biophys., 152, 318, 1972) for culturing fibroblasts. Collagen synthesis ability using cells was tested. That is, this test method uses 3 H after adding the sample to the cell culture system.
By incorporating labeled proline, the amount of collagen synthesis of cells is quantified. The present inventors screened various substances arbitrarily selected from animals and plants and fungi for their collagen synthesis promoting action by the above-mentioned test method, and as a result, they found that the fractional components of the placenta had high collagen synthesis promoting activity. It was That is, it became clear that the placental collagen synthesis-promoting component is transferred to the placenta acid / alcohol-soluble fraction, and thus the collagen synthesis-promoting agent of the present invention containing abundant collagen synthesis-promoting component was completed. It was Furthermore, when the present inventors prepared a skin cosmetic containing the collagen synthesis promoter of the present invention and applied it to the skin, the skin function was enhanced to prevent wrinkles on the skin, and to make the skin delicate and moist. Was found and its high safety was confirmed, so that the skin cosmetic of the present invention was completed. The skin cosmetic containing the collagen synthesis promoter of the present invention was considered to exhibit its effect by promoting collagen synthesis of dermal fibroblasts.
【０００６】一方、従来よりコラーゲン合成促進作用を
有する物質として細胞成長因子ＴＧＦ（発癌増殖因子）
の一つであるＴＧＦ−βがWrana らにより報告されてい
る（Eur. J. Biochem., 159, 69-76, 1986）。これは、
分子量23,000〜25,000のペプチドであり（Biochemistr
y, 22, 5692-5698, 1983 、J. Biol. Chem., 259, 9756
-9761, 1984) 、ＴＧＦ−αとともに多くの腫瘍細胞で
産生される主な増殖因子である。ＴＧＦ（昔はＳＧＦと
も呼ばれいた（組織培養，８，39-45 ，1982））には、
いくつかの分子種が報告されているが、現段階でのＴＧ
Ｆの普遍的な性質は、正常細胞を軟寒天培地中でコロニ
ーを形成させうることと考えられている。Todaroらによ
るとMolony肉腫ウイルス（ＭＳＶ）で形質転換したマウ
ス３Ｔ３細胞が、その培養無血清培地中に正常細胞を悪
性細胞様に転換させる作用をもつ因子（ＳＧＦ）を産生
していることを報告している（Federation Proc., 41,
2996-3003, 1982）。このようなＴＧＦ活性を有するＴ
ＧＦ−βをもって、コラーゲン合成促進作用を期待しヒ
トに塗布することは、非常に危険であるといわざるを得
ず、化粧品に配合する場合においても、安全性において
好ましくなく、イメージ的にもマイナスである。本発明
者らはこのような点に鑑み、安全性が高く、かつ安定性
の良いコラーゲン合成促進剤の研究を行い、本発明を完
成した。また、これまで胎盤抽出液のコラーゲン合成促
進作用、または皮膚化粧料へ配合した場合の本作用に起
因する有用性に関し全く研究されておらず、本発明者ら
により初めて明らかにされたものである。On the other hand, cell growth factor TGF (carcinogenic growth factor) has been conventionally used as a substance having a collagen synthesis promoting action.
One of them, TGF-β, has been reported by Wrana et al. (Eur. J. Biochem., 159, 69-76, 1986). this is,
It is a peptide with a molecular weight of 23,000 to 25,000 (Biochemistr
y, 22, 5692-5698, 1983, J. Biol. Chem., 259, 9756.
-9761, 1984), together with TGF-α, is a major growth factor produced in many tumor cells. TGF (formerly known as SGF (tissue culture, 8, 39-45, 1982))
Although several molecular species have been reported, TG at this stage
The universal nature of F is believed to allow normal cells to colonize in soft agar. According to Todaro et al., Molony sarcoma virus (MSV) -transformed mouse 3T3 cells produce a factor (SGF), which has the effect of converting normal cells into malignant cells, in its serum-free medium. (Federation Proc., 41,
2996-3003, 1982). T having such TGF activity
It cannot be said that applying GF-β to humans in the expectation of a collagen synthesis promoting action is extremely dangerous, and it is unfavorable in terms of safety when incorporated into cosmetics, and it is also negative in terms of image. Is. In view of these points, the present inventors have conducted research on a collagen synthesis promoter having high safety and good stability, and completed the present invention. In addition, until now, no research has been conducted on the collagen synthesis promoting action of the placenta extract, or the usefulness resulting from this action when incorporated into a skin cosmetic, and it was first revealed by the present inventors. .
【０００７】また本発明のコラーゲン合成促進剤及び皮
膚化粧料は組織損傷時、創傷部に遊走した線維芽細胞に
より形成される肉芽組織に作用し、そのコラーゲン合成
を促進し真皮の再構築を促すことにより創傷治癒効果を
有することも期待される。即ち、本発明は真皮の線維芽
細胞のコラーゲン合成を促進し、老化制御機能を有する
胎盤由来のコラーゲン合成促進剤及びその製造法及びそ
れを含有する新規皮膚化粧料を提供することを目的とす
る。以下、本発明につき詳述する。本発明に至る過程で
用いた先述のコラーゲン合成促進能試験法は本発明のコ
ラーゲン合成促進作用を制限するものではなく、細胞レ
ベルでコラーゲン合成能を検出し得る他の試験法、例え
ば、放射性同位元素で標識したヒドロキシプロリンを用
いる免疫学的方法，コラーゲンの抗体を用いる免疫学的
方法，コラーゲンのｍＲＮＡを核酸プローブとハイブリ
ダイズさせ検出する方法等をin vitro，in vivo ，in s
itu で利用することができる。Further, the collagen synthesis promoter and the skin cosmetic of the present invention act on the granulation tissue formed by fibroblasts that have migrated to the wound at the time of tissue damage, promote the collagen synthesis and promote the reconstruction of the dermis. Therefore, it is also expected to have a wound healing effect. That is, an object of the present invention is to provide a placenta-derived collagen synthesis promoter having a function of controlling senescence, which promotes collagen synthesis of dermal fibroblasts, a method for producing the same, and a novel skin cosmetic containing the same. . Hereinafter, the present invention will be described in detail. The above-mentioned collagen synthesis promoting ability test method used in the process leading to the present invention does not limit the collagen synthesis promoting action of the present invention, and other test methods capable of detecting collagen synthesis ability at the cellular level, for example, radioisotope Immunological methods using hydroxyproline labeled with elements, immunological methods using collagen antibodies, methods for detecting collagen mRNA by hybridizing it with a nucleic acid probe, etc. in vitro, in vivo, in s
It can be used in situ.
【０００８】本発明に使用する胎盤は、ヒト，ウシ，ヤ
ギ，ヒツジ，ブタ等の哺乳動物から採取された新鮮な胎
盤、あるいはその胎盤をミンチ状にしたものが用いられ
る。なお、懐胎中のウシ，ヤギ，ヒツジ，ブタの胎盤の
分画成分には、コラーゲン合成促進作用が特に高いこと
が明らかとなり、生理学上重要な意味を持つものと考え
られる。本発明のコラーゲン合成促進剤の調製に当たっ
ては、胎盤に水を加えた後、酸及びアルコールを別々に
加えるかまたは酸・アルコール混液として加え最終ｐＨ
１〜６に調整するか、又はアルコール濃度１０〜５０％
（Ｖ／Ｖ）に調整し、好ましくはｐＨ２〜５．５に調整
するか、又はアルコール濃度２０〜４０％（Ｖ／Ｖ）に
調整する。更に好ましくはｐＨ１〜６かつアルコール濃
度１０〜５０％（Ｖ／Ｖ）に調整し、もっとも好ましく
はｐＨ２〜５．５かつアルコール濃度２０〜４０％（Ｖ
／Ｖ）に調製する。ｐＨ１未満またはアルコール濃度５
０％（Ｖ／Ｖ）以上ではコラーゲン合成促進作用の作用
成分が失活あるいは不溶化を起こす。またｐＨ６以上ま
たはアルコール濃度１０％（Ｖ／Ｖ）以下、あるいは酸
もしくはアルコールのどちらか一方だけの処理では不必
要な画分を除去し得ず、分画効率は著しく低下する。The placenta used in the present invention is a fresh placenta collected from mammals such as humans, cows, goats, sheep and pigs, or a minced placenta. In addition, it was revealed that the fractional components of the placenta of bovine, goat, ovine, and porcine pregnant women have a particularly high collagen synthesis promoting action, which is considered to have important physiological significance. In the preparation of the collagen synthesis promoter of the present invention, water is added to the placenta, and then acid and alcohol are added separately or as an acid / alcohol mixture to give a final pH.
Adjust to 1-6 or alcohol concentration 10-50%
(V / V), preferably pH 2 to 5.5 or alcohol concentration 20 to 40% (V / V). More preferably, the pH is adjusted to 1 to 6 and the alcohol concentration is 10 to 50% (V / V), and most preferably, the pH is 2 to 5.5 and the alcohol concentration is 20 to 40% (V).
/ V). pH less than 1 or alcohol concentration 5
At 0% (V / V) or more, the active ingredient for promoting collagen synthesis is inactivated or insolubilized. Further, unnecessary fractions cannot be removed by treatment with a pH of 6 or more or an alcohol concentration of 10% (V / V) or less, or treatment with either acid or alcohol, and the fractionation efficiency is markedly reduced.
【０００９】なお、使用するアルコールはメタノール，
エタノール，イソプロパノール，ｎ−ブタノールなど任
意のものが用いられるが好ましくはエタノールが用いら
れる。また、使用する酸も塩酸，酢酸，乳酸，硫酸，ク
エン酸，リン酸など任意のものが用いられるが好ましく
は塩酸が用いられ、またその濃度も任意であるが、操作
性，安全性の面からも０．５〜５Ｎが好ましい。このよ
うに酸・アルコール処理して生じる不溶物は、ろ過，遠
心分離又はデカンテーション等により除去し、目的とす
るコラーゲン合成促進作用成分を豊富に含有するコラー
ゲン合成促進剤が得られる。なお、酸・アルコール処理
して生じる不溶物を除去する際の工程としてはろ過、遠
心分離またはデカンテーションがあげられるが、好まし
くはろ過または遠心分離が良い。工程の具体例を示すと
次のとおりである。ろ過としては、自然ろ過，吸引ろ
過，加圧ろ過，圧搾ろ過などがあげられるが、好ましく
は吸引ろ過，加圧ろ過，圧搾ろ過、更に好ましくは加圧
ろ過があげられる。またろ過の際にケイソウ土などのろ
過助剤を加えてろ過すると効率的であり、添加量も任意
であるが、液重量当たり０．５〜１０％（Ｗ／Ｗ）の範
囲の添加が好ましく、更に好ましくは１〜５％（Ｗ／
Ｗ）である。遠心分離の場合、機種により違いがある
が、不溶物が沈殿する条件であれば問題はなく、通常２
０００ｒｐｍ以上の回転数が好ましく、時間節約の面か
らも更に好ましくは回転数５０００ｒｐｍ以上、もっと
も好ましくは回転数８０００ｒｐｍ以上である。また、
遠心ろ過機などの連続遠心機も利用できる。デカンテー
ションとしては、傾しゃ法の他、サイホン，フィルター
ステッキも利用できる。The alcohol used is methanol,
Any of ethanol, isopropanol, n-butanol and the like can be used, but ethanol is preferably used. The acid used may be any of hydrochloric acid, acetic acid, lactic acid, sulfuric acid, citric acid, phosphoric acid, etc., but hydrochloric acid is preferably used, and its concentration is also arbitrary, but in terms of operability and safety. Also, 0.5 to 5 N is preferable. The insoluble matter generated by the acid / alcohol treatment in this way is removed by filtration, centrifugation, decantation, or the like to obtain a target collagen synthesis-promoting agent rich in the collagen synthesis-promoting action component. The process for removing the insoluble matter generated by the acid / alcohol treatment may be filtration, centrifugation or decantation, preferably filtration or centrifugation. A specific example of the process is as follows. Examples of the filtration include natural filtration, suction filtration, pressure filtration, compression filtration, etc., preferably suction filtration, pressure filtration, compression filtration, and more preferably pressure filtration. Further, it is efficient to add a filter aid such as diatomaceous earth at the time of filtration, and the addition amount is optional, but addition in the range of 0.5 to 10% (W / W) per liquid weight is preferable. , And more preferably 1 to 5% (W /
W). In the case of centrifugation, there is a difference depending on the model, but there is no problem as long as the insoluble matter precipitates.
The rotation speed is preferably 000 rpm or more, more preferably 5000 rpm or more, and most preferably 8000 rpm or more from the viewpoint of time saving. Also,
A continuous centrifuge such as a centrifugal filter can also be used. As a decantation, a siphon or a filter stick can be used in addition to the tilting method.
【００１０】更に、コラーゲン合成促進剤は必要に応じ
てｐＨを調整し、ゲルろ過又は限外ろ過にて分子量１万
以上の高分子を除去しても活性は失われることはなく、
更に、活性炭，活性白土，合成吸着剤などの吸着剤や陰
イオン及び陽イオン交換樹脂により分画してもよく、カ
ラム法，バッチ法いずれでも構わない。なお、化粧品へ
の配合上、分子量１万以上の高分子を除去した方が好ま
しい。また、このコラーゲン合成促進剤は減圧濃縮，限
外ろ過又は凍結濃縮等の方法により濃縮してもよく、ま
た、凍結乾燥，噴霧乾燥又は平板乾燥などの方法により
乾燥粉末化することも可能である。Furthermore, the activity of the collagen synthesis promoter is not lost even if the pH is adjusted as necessary and the polymer having a molecular weight of 10,000 or more is removed by gel filtration or ultrafiltration.
Further, it may be fractionated by an adsorbent such as activated carbon, activated clay, a synthetic adsorbent or the like, an anion and cation exchange resin, and either a column method or a batch method may be used. In addition, it is preferable to remove a polymer having a molecular weight of 10,000 or more from the viewpoint of blending into cosmetics. Further, this collagen synthesis promoter may be concentrated by a method such as vacuum concentration, ultrafiltration or freeze concentration, or may be dried and powdered by a method such as freeze drying, spray drying or flat plate drying. .
【００１１】本発明の皮膚化粧料には上記したコラーゲ
ン合成促進剤のほか、化粧料一般に用いられる界面活性
剤，油脂類，多価アルコール，低級アルコール，増粘
剤，紫外線吸収剤・散乱剤，防腐剤，酸化防止剤，キレ
ート剤，ｐＨ調整剤，香料，色素，水等を適宜配合する
ことができる。これらの添加成分の具体例を示すと次の
とおりである。界面活性剤としてはポリオキシエチレン
（以下ＰＯＥ−と略す）オクチルドデシルアルコール、
ＰＯＥ−２−デシルテトラデシルアルコール等のＰＯＥ
−分岐アルキルエーテル、ＰＯＥ−オレイルアルコール
エーテル、ＰＯＥ−セチルアルコールエーテル等のＰＯ
Ｅ−アルキルエーテル、ソルビタンモノオレエート、ソ
ルビタンモノイソステアレート、ソルビタンモノラウレ
ート等のソルビタンエステル、ＰＯＥ−ソルビタンモノ
オレエート、ＰＯＥ−ソルビタンモノイソステアレー
ト、ＰＯＥ−ソルビタンモノラウレート等のＰＯＥ−ソ
ルビタンエステル、グリセリルモノオレエート、グリセ
リルモノステアレート、グリセリルモノミリステート等
のグリセリン脂肪酸エステル、ＰＯＥ−グリセリルモノ
オレエート、ＰＯＥ−グリセリルモノステアレート、Ｐ
ＯＥ−グリセリルモノミリステート等のＰＯＥ−グリセ
リン脂肪酸エステル、ＰＯＥ−ジヒドロコレステロール
エステル、ＰＯＥ−硬化ヒマシ油、ＰＯＥ−硬化ヒマシ
油イソステアレート等のＰＯＥ−硬化ヒマシ油脂肪酸エ
ステル、ＰＯＥ−オクチルフェノールエーテル等のＰＯ
Ｅ−アルキルアリールエーテル、グリセロールモノイソ
ステアレート、グリセロールモノミリステート等のグリ
セロールエステル、ＰＯＥ−グリセロールモノイソステ
アレート、ＰＯＥ−グリセロールモノミリステート等の
ＰＯＥ−グリセロールエーテル、ジグリセリルモノステ
アレート、デカグリセリルデカステアレート、デカグリ
セリルデカイソステアレート、ジグリセリルジイソステ
アレート等のポリグリセリン脂肪酸エステル等の非イオ
ン界面活性剤、ミリスチン酸、ステアリン酸、パルミチ
ン酸、ベヘニン酸、イソステアリン酸、オレイン酸等の
高級脂肪酸のカリウム、ナトリウム、ジエタノールアミ
ン、トリエタノールアミン、アミノ酸等の塩、エーテル
カルボン酸の上記アルカリ塩、Ｎ−アシルアミノ酸の
塩、Ｎ−アシルサルコン酸塩、高級アルキルスルホン酸
塩等の陰イオン界面活性剤、アルキルアミン塩、ポリア
ミン、アミノアルコール脂肪酸有機シリコーン樹脂、ア
ルキル４級アンモニウム塩等の陽イオン界面活性剤ある
いはレシチン、ベタイン誘導体等の両性界面活性剤等。
油脂類としては、ヒマシ油、オリーブ油、カカオ油、椿
油、ヤシ油、木ロウ、ホホバ油、グレープシード油、ア
ボガド油等の植物油脂類、ミンク油、卵黄油等の動物油
脂類、ミツロウ、鯨ロウ、ラノリン、カルナウバロウ、
キャンデリラロウ等のロウ類、流動パラフィン、スクワ
レン、マイクロクリスタリンワックス、セレシンワック
ス、パラフィンワックス、ワセリン等の炭化水素類、ラ
ウリン酸、ミリスチン酸、ステアリン酸、オレイン酸、
イソステアリン酸、ベヘニン酸等の天然及び合成脂肪酸
類、セタノール、ステアリルアルコール、ヘキシルデカ
ノール、オクチルデカノール、ラウリルアルコール等の
天然及び高級アルコール類、ミリスチン酸イソプロピ
ル、パルミチン酸イソプロピル、ミリスチン酸オクチル
ドデシル、オレイン酸オクチルドデシル、コレステロー
ルオレート等のエステル類。多価アルコールとしてはエ
チレングリコール、ポリエチレングリコール、プロピレ
ングリコール、１，３−ブチレングリコール、１，４−
ブチレングリコール、ジプロピレングリコール、グリセ
リン、ジグリセリン、トリグリセリン、テトラグリセリ
ン等のポリグリセリン、グルコース、マルトース、マル
チトース、ショ糖、フルクトース、キシリトース、ソル
ビトール、マルトトリオース、スレイトール、エリスリ
トール等。増粘剤としては、アルギン酸ナトリウム、キ
サンタンガム、硅酸アルミニウム、マルメロ種子抽出
物、トラガントガム、デンプン、コラーゲン、ヒアルロ
ン酸ナトリウム等の天然高分子物質、メチルセルロー
ス、ヒドロキシエチルセルロース、カルボキシメチルセ
ルロース、可溶性デンプン、カチオン化セルロース等の
半合成高分子物質、カルボキシビニルポリマー、ポリビ
ニルアルコール等の合成高分子物質等。紫外線吸収剤と
しては、パラアミノ安息香酸、パラメトキシケイ皮酸イ
ソプロピル、ブチルメトキシベンゾイルメタン、グリセ
リル−モノ−２−エチルヘキサノイル−ジ−パラメトキ
シベンゾフェノン、ジガロイルトリオレエート、２−
２’−ジヒドキシ−４−メトキシベンゾフェノン、エチ
ル−４−ビスヒドロキシプロピルアミノベンゾエート、
２−エチルヘキシル−２−シアノ−３，３’−ジフェニ
ルアクリレート、パラメトキシケイ皮酸エチルヘキシ
ル、サリチル酸−２−エチルヘキシル、グリセリルパラ
アミノベンゾエート、サリチル酸ホモメチル、オルトア
ミノ安息香酸メチル、２−ヒドロキシ−４−メトキシベ
ンゾフェノン、アミル−パラ−ジメチルアミノベンゾエ
ート、２−フェニルベンゾイミダゾール−５−スルフォ
ン酸、２−ヒドロキシ−４−メトキシベンゾフェノン−
５−スルフォン酸等。防腐剤としては、安息香酸塩、サ
リチル酸塩、ソルビン酸塩、デヒドロ酢酸塩、パラオキ
シ安息香酸エステル、２，４，４’−トリクロロ−２’
−ヒドロキシジフェニルエーテル、３，４，４’−トリ
クロロカルバニリド、塩化ベンザルコニウム、ヒノキチ
オール、レゾルシン、エタノール等。酸化防止剤として
は、トコフェロール、アスコルビン酸、ブチルヒドロキ
シアニソール、ジブチルヒドロキシトルエン、ノルジヒ
ドログアヤレチン酸、没食子酸プロピル等。キレート剤
としては、エデト酸ナトリウム、クエン酸ナトリウム
等。これらの添加成分の中には、本発明の必須成分の安
定性または経皮吸収性を高めることにより、本発明の皮
膚化粧料の有効性をより向上させる働きをもつものもあ
る。また、その剤型も任意であり、更に可溶系，乳化
系，粉末分散系等何れでもよく、用途も化粧水，乳液，
クリーム，パック等の基礎化粧料はもちろんファンデー
ション等のメーキャップ化粧料など幅広く利用できる。In addition to the above-mentioned collagen synthesis promoter, the skin cosmetics of the present invention include surfactants, oils and fats, polyhydric alcohols, lower alcohols, thickeners, ultraviolet absorbers / scattering agents, which are commonly used in cosmetics. Preservatives, antioxidants, chelating agents, pH adjusters, fragrances, dyes, water and the like can be added as appropriate. Specific examples of these additive components are as follows. As the surfactant, polyoxyethylene (hereinafter abbreviated as POE-) octyldodecyl alcohol,
POE-2-POC such as decyl tetradecyl alcohol
-PO such as branched alkyl ether, POE-oleyl alcohol ether, POE-cetyl alcohol ether
POE- such as E-alkyl ether, sorbitan monooleate, sorbitan monoisostearate and sorbitan monolaurate, POE-sorbitan monooleate, POE-sorbitan monoisostearate and POE-sorbitan monolaurate Glycerin fatty acid esters such as sorbitan ester, glyceryl monooleate, glyceryl monostearate, glyceryl monomyristate, POE-glyceryl monooleate, POE-glyceryl monostearate, P
POE-glycerin fatty acid ester such as OE-glyceryl monomyristate, POE-dihydrocholesterol ester, POE-hardened castor oil, POE-hardened castor oil, POE-hardened castor oil fatty acid ester such as isostearate, POE-octylphenol ether, etc. PO
E-alkyl aryl ether, glycerol monoisostearate, glycerol ester such as glycerol monomyristate, POE-glycerol monoisostearate, POE-glycerol ether such as POE-glycerol monomyristate, diglyceryl monostearate, decaglyceryl Non-ionic surfactants such as deglycerate, decaglyceryl decaisostearate, polyglycerin fatty acid esters such as diglyceryl diisostearate, myristic acid, stearic acid, palmitic acid, behenic acid, isostearic acid, oleic acid, etc. Salts of higher fatty acids such as potassium, sodium, diethanolamine, triethanolamine, amino acids, the above-mentioned alkali salts of ether carboxylic acids, salts of N-acyl amino acids, N-acyl monkeys. Anionic surfactants such as phosphates and higher alkyl sulfonates, cationic amines such as alkylamine salts, polyamines, amino alcohol fatty acid organic silicone resins, alkyl quaternary ammonium salts, and amphoteric amphoteric compounds such as lecithin and betaine derivatives. Surfactants, etc.
Examples of oils and fats include castor oil, olive oil, cocoa oil, camellia oil, coconut oil, wood wax, jojoba oil, grape seed oil, vegetable oils such as avocado oil, animal oils such as mink oil and egg yolk oil, beeswax, whale. Wax, lanolin, carnauba wax,
Waxes such as candelilla wax, liquid paraffin, squalene, microcrystalline wax, ceresin wax, paraffin wax, hydrocarbons such as petrolatum, lauric acid, myristic acid, stearic acid, oleic acid,
Natural and synthetic fatty acids such as isostearic acid and behenic acid, natural and higher alcohols such as cetanol, stearyl alcohol, hexyldecanol, octyldecanol and lauryl alcohol, isopropyl myristate, isopropyl palmitate, octyldodecyl myristate, octyl oleate. Esters such as dodecyl and cholesterol oleate. As the polyhydric alcohol, ethylene glycol, polyethylene glycol, propylene glycol, 1,3-butylene glycol, 1,4-
Polyglycerin such as butylene glycol, dipropylene glycol, glycerin, diglycerin, triglycerin and tetraglycerin, glucose, maltose, maltose, sucrose, fructose, xylitolose, sorbitol, maltotriose, threitol, erythritol and the like. As the thickener, sodium alginate, xanthan gum, aluminum silicate, quince seed extract, tragacanth gum, starch, collagen, natural polymer substances such as sodium hyaluronate, methyl cellulose, hydroxyethyl cellulose, carboxymethyl cellulose, soluble starch, cationized cellulose. Semi-synthetic polymer substances such as, carboxyvinyl polymer, synthetic polymer substances such as polyvinyl alcohol, etc. As the ultraviolet absorber, paraaminobenzoic acid, isopropyl paramethoxycinnamate, butylmethoxybenzoylmethane, glyceryl-mono-2-ethylhexanoyl-di-paramethoxybenzophenone, digaroyltrioleate, 2-
2'-dihydroxy-4-methoxybenzophenone, ethyl-4-bishydroxypropylaminobenzoate,
2-ethylhexyl-2-cyano-3,3'-diphenyl acrylate, ethyl hexyl paramethoxycinnamate, 2-ethylhexyl salicylate, glyceryl paraaminobenzoate, homomethyl salicylate, methyl orthoaminobenzoate, 2-hydroxy-4-methoxybenzophenone, Amyl-para-dimethylaminobenzoate, 2-phenylbenzimidazole-5-sulfonic acid, 2-hydroxy-4-methoxybenzophenone-
5-sulfonic acid and the like. Preservatives include benzoate, salicylate, sorbate, dehydroacetate, paraoxybenzoate, 2,4,4'-trichloro-2 '.
-Hydroxydiphenyl ether, 3,4,4'-trichlorocarbanilide, benzalkonium chloride, hinokitiol, resorcin, ethanol and the like. Examples of antioxidants include tocopherol, ascorbic acid, butylhydroxyanisole, dibutylhydroxytoluene, nordihydroguaiaretic acid, propyl gallate and the like. Examples of chelating agents include sodium edetate and sodium citrate. Some of these added components have a function of further improving the effectiveness of the skin cosmetic of the present invention by increasing the stability or transdermal absorbability of the essential components of the present invention. Further, its dosage form is also arbitrary, and may be any soluble system, emulsion system, powder dispersion system, etc.
Not only basic cosmetics such as creams and packs but also makeup cosmetics such as foundations can be widely used.
【００１２】[0012]
【実施例】以下に本発明の実施例を示すが、これらによ
って本発明を制限するものではない。コラーゲン合成促
進剤の調製法と培地への添加量について述べる。なお、
コラーゲン合成促進剤の調製は培養細胞に直接添加する
ことを考慮して、限外濾過や減圧濃縮にてアルコールを
除去し、かつｐＨを中性（ｐＨ６．５〜７．５）に調整
したが、これによって本発明のコラーゲン合成促進剤を
制限するものではない。また、本発明の特色は、酸・ア
ルコール処理可溶画分に豊富なコラーゲン合成促進作用
成分が含有されることにあり、コラーゲン合成促進剤の
調製法に示したように、更に活性成分の濃度を上げ、熱
安定性を良くし、脱色・脱臭するために、濃縮，加熱処
理，活性炭等を用いた吸着剤処理などの種々の工程を行
うことは化粧料への配合上有利であるが、これらによっ
て本発明のコラーゲン合成促進剤を制限するものではな
い。EXAMPLES Examples of the present invention will be shown below, but the present invention is not limited thereto. The method for preparing the collagen synthesis promoter and the amount added to the medium will be described. In addition,
In preparation of the collagen synthesis promoter, alcohol was removed by ultrafiltration or vacuum concentration and the pH was adjusted to neutral (pH 6.5 to 7.5) in consideration of direct addition to cultured cells. However, this does not limit the collagen synthesis promoter of the present invention. Further, the feature of the present invention is that the soluble fraction treated with acid / alcohol contains abundant components for promoting collagen synthesis, and as described in the method for preparing a collagen synthesis accelerator, the concentration of the active ingredient is further increased. In order to improve the heat stability, improve the heat stability, and decolorize and deodorize, various steps such as concentration, heat treatment, adsorbent treatment using activated carbon, etc. are advantageous in blending into cosmetics, These do not limit the collagen synthesis promoter of the present invention.
【００１３】試料Ａ ウシ胎盤由来のコラーゲン合成促
進剤 ウシの胎盤３００ｇを水１ｌに懸濁し、１Ｎ塩酸でｐＨ
４．０に調整し、エタノール３００ｍｌを加え、２時間
撹拌した。その後生じた沈殿物を遠心分離によって除去
し、その上清を分画分子量１０００の限外ろ過膜にて５
００ｇまで濃縮し、ｐＨ７．０に調整し、７０℃，１時
間加熱処理を行った後、生成した不溶物を吸引ろ過によ
り取り除き、清澄な胎盤分画成分を得た。Sample A Collagen synthesis promoter derived from bovine placenta 300 g of bovine placenta was suspended in 1 liter of water, and the pH was adjusted with 1N hydrochloric acid.
The mixture was adjusted to 4.0, 300 ml of ethanol was added, and the mixture was stirred for 2 hours. The resulting precipitate was removed by centrifugation, and the supernatant was filtered with an ultrafiltration membrane having a molecular weight cut off of 1000.
The solution was concentrated to 00 g, adjusted to pH 7.0, heat-treated at 70 ° C. for 1 hour, and the insoluble matter formed was removed by suction filtration to obtain a clear placental fraction component.
【００１４】試料Ｂ ウシ胎盤由来のコラーゲン合成促
進剤 ウシの胎盤３００ｇを水１ｌに懸濁し、５Ｎ酢酸でｐＨ
３．０に調整し、メタノール４００ｍｌを加え、２時間
撹拌した。その後デカンテーションにより上清を分取
し、その液をｐＨ７．５に調整し、減圧下５００ｇまで
濃縮後吸引ろ過し、清澄な胎盤分画成分を得た。Sample B Collagen synthesis promoter derived from bovine placenta 300 g of bovine placenta was suspended in 1 liter of water, and the pH was adjusted with 5N acetic acid.
The mixture was adjusted to 3.0, 400 ml of methanol was added, and the mixture was stirred for 2 hours. Then, the supernatant was separated by decantation, the pH of the solution was adjusted to 7.5, and the solution was concentrated to 500 g under reduced pressure and suction filtered to obtain a clear placental fraction component.
【００１５】試料Ｃ ヤギ胎盤由来のコラーゲン合成促
進剤 ヤギの胎盤３００ｇを水１ｌに懸濁し、２Ｎ乳酸でｐＨ
４．５に調整し、ｎ−ブタノール５００ｍｌを加え、２
時間撹拌した。その後遠心分離し、その上清を減圧下５
００ｇまで濃縮し、ｐＨ６．５に調整し、吸引ろ過し清
澄な液を得た。Sample C Collagen synthesis promoter derived from goat placenta 300 g of goat placenta was suspended in 1 liter of water, and the pH was adjusted with 2N lactic acid.
Adjust to 4.5, add 500 ml of n-butanol and add 2
Stirred for hours. After that, centrifuge, and the supernatant is decompressed.
The solution was concentrated to 00 g, adjusted to pH 6.5, and suction filtered to obtain a clear liquid.
【００１６】試料Ｄ ブタ胎盤由来のコラーゲン合成促
進剤 ブタの胎盤３００ｇを水１ｌに懸濁し、３Ｎクエン酸で
ｐＨ５．５に調整し、イソプロパノール４００ｍｌを加
え、２時間撹拌した。その後セライトろ過し、その液を
ｐＨ７．５に調整し、減圧下５００ｇまで濃縮し、凍結
乾燥にて乾燥粉末化させ、得られた乾燥粉末を１００ｇ
の水に溶解した。Sample D Pig Placenta-Derived Collagen Synthesis Promoter 300 g of pig placenta was suspended in 1 liter of water, the pH was adjusted to 5.5 with 3N citric acid, 400 ml of isopropanol was added, and the mixture was stirred for 2 hours. After that, the mixture is filtered through Celite, the pH is adjusted to 7.5, concentrated to 500 g under reduced pressure, freeze-dried to give a dry powder, and 100 g of the obtained dry powder is obtained.
Dissolved in water.
【００１７】試料Ｅ ヒト胎盤由来のコラーゲン合成促
進剤 ヒトの胎盤３００ｇを水１ｌに懸濁し、６Ｎ塩酸でｐＨ
４．０に調整し、エタノール３００ｍｌを加え、２時間
撹拌した。その後セライトろ過し、その液を減圧下５０
０ｇまで濃縮し、ｐＨ７．５に調整し、８０℃，１０分
間加熱処理を行った後、生成した不溶物を吸引ろ過によ
り取り除き、清澄な胎盤分画成分を得た。Sample E Collagen synthesis promoter derived from human placenta 300 g of human placenta was suspended in 1 liter of water, and the pH was adjusted with 6N hydrochloric acid.
The mixture was adjusted to 4.0, 300 ml of ethanol was added, and the mixture was stirred for 2 hours. After that, it is filtered through Celite, and the liquid is reduced to 50
After concentrating to 0 g, adjusting the pH to 7.5 and performing heat treatment at 80 ° C. for 10 minutes, the generated insoluble matter was removed by suction filtration to obtain a clear placental fraction component.
【００１８】試料Ｆ ウシ胎盤由来のコラーゲン合成促
進剤 試料ＡをｐＨ８．５，０．０１Ｍ燐酸緩衝液にて平衡化
したＤＥＡＥセルロファインに吸着させ、ｐＨ８．５，
０．８ＭＮａＣｌ，０．０１Ｍ燐酸緩衝液にて溶出さ
せ、その溶出液を４℃，１２時間透析を行った。Sample F Collagen synthesis promoter derived from bovine placenta Sample A was adsorbed on DEAE cellulofine equilibrated with pH 8.5, 0.01 M phosphate buffer, and pH 8.5 was obtained.
Elution was performed with 0.8 M NaCl and 0.01 M phosphate buffer, and the eluate was dialyzed at 4 ° C. for 12 hours.
【００１９】試料Ｇ ウシ胎盤由来のコラーゲン合成促
進剤 試料Ｂにヤシガラ炭（武田薬品製）を２％添加し、よく
撹拌後吸引ろ過により清澄な液を得た。この液を分画分
子量１万の限外ろ過膜にて高分子を除去し、凍結乾燥に
て乾燥粉末化後、得られた乾燥粉末を１００ｇの水に溶
解した。 添加量（Ｖ／Ｖ培養液％） 試料Ａ ： ２％ 試料Ｂ ： ２％ 試料Ｃ ： ２％ 試料Ｄ ： １％ 試料Ｅ ： ２％ 試料Ｆ ： ２％ 試料Ｇ ： １％ 表１より明らかなように本発明のコラーゲン合成促進剤
は、線維芽細胞のコラーゲン合成を促進することが明ら
かとなった。かくして得られる本発明のコラーゲン合成
促進剤及びそれを含有する皮膚化粧料の有効性及び安全
性について試験した結果は、次の通りである。Sample G Collagen synthesis promoter derived from bovine placenta To sample B, 2% of coconut husk charcoal (manufactured by Takeda Pharmaceutical Co., Ltd.) was added, and after thorough stirring, a clear liquid was obtained by suction filtration. The polymer was removed from this liquid by an ultrafiltration membrane having a molecular weight cut off of 10,000, and the powder was freeze-dried to give a dry powder. The obtained dry powder was dissolved in 100 g of water. Addition amount (V / V culture solution%) Sample A: 2% Sample B: 2% Sample C: 2% Sample D: 1% Sample E: 2% Sample F: 2% Sample G: 1% Table 1 Thus, it was revealed that the collagen synthesis promoter of the present invention promotes collagen synthesis of fibroblasts. The results of testing the efficacy and safety of the thus-obtained collagen synthesis promoter of the present invention and the skin cosmetics containing the same are as follows.
【００２０】試験例１．培養線維芽細胞のコラーゲン合
成促進能試験 継代培養してきたＷＩ−３８細胞（ヒト胎児肺正常２倍
体細胞）に、ＭＥＭ培地（０．５％牛胎児血清含有）の
低血清培養条件下で本発明のコラーゲン合成促進剤を試
料として添加後、５％ＣＯ2 ＋９５％Ａｉｒにて３７
℃，４日間培養し、培地５ｍｌ中に3Ｈ-プロリン（200
μＣｉ／ｍｌ）を５０μｌ添加して、５％ＣＯ2＋Ａｉ
ｒにて３７℃，６時間培養した。なお、試料無添加区を
対照とした。その後培養上清を取り除き、細胞画分にコ
ラゲナーゼタイプIII(Worthing ton社製）５units ／ｍ
ｌを３７℃，１８時間作用させ、トリクロロ酢酸溶液で
除蛋白を行い、その可溶画分をハイオニックフローと混
合し放射線量を測定した。その結果を表１に示す。Test Example 1. Collagen synthesis promoting ability test of cultured fibroblasts WI-38 cells (human fetal lung normal diploid cells) that have been subcultured are cultured under low serum culture conditions of MEM medium (containing 0.5% fetal bovine serum). After adding the collagen synthesis promoter of the present invention as a sample, the mixture was added with 5% CO 2 + 95% Air to 37
Cultivate at 4 ℃ for 4 days and add 3 H-proline (200
(50 μCi / ml) and added 5% CO 2 + Ai
Incubated at 37 ° C for 6 hours at r. The sample-free area was used as a control. After that, the culture supernatant was removed, and collagenase type III (Worthing ton) 5 units / m was added to the cell fraction.
1 was allowed to act at 37 ° C. for 18 hours, deproteinization was carried out with a trichloroacetic acid solution, and the soluble fraction was mixed with Hyonic Flow to measure the radiation dose. Table 1 shows the results.
【００２１】[0021]
【表１】 [Table 1]
【００２２】試験例２．パネルテスト 小皺の悩みを有する３２〜５１歳（平均年齢４０．５
歳）の女性５０名を対象にして、下記の本発明皮膚化粧
料及び対照皮膚化粧料を、１日２回（朝，夕）連続３ヶ
月塗布、使用せしめた結果の官能評価を表２に示した。Test Example 2. Panel test 32-51 years old with wrinkles (average age 40.5
Table 2 shows the sensory evaluation of the results obtained by applying the following skin cosmetics and control skin cosmetics twice a day (morning and evening) for 3 consecutive months to 50 women aged 50 years. Indicated.
【００２３】[0023]
【表２】 [Table 2]
【００２４】 〈本発明皮膚化粧料〉 試験例１の試料Ａ（対照皮膚化粧料は精製水） ２０％ グリセリン ５％ エタノール ５％ メチルパラベン ０．２％ 精製水 ６９．８％ 表２より明らかなように、本発明の皮膚化粧料は高い有
効性を示すことが明らかとなった。<Inventive Skin Cosmetic> Sample A of Test Example 1 (control skin cosmetic is purified water) 20% Glycerin 5% Ethanol 5% Methylparaben 0.2% Purified water 69.8% As is clear from Table 2. Moreover, it was revealed that the skin cosmetic composition of the present invention exhibits high effectiveness.
【００２５】試験例３．パッチテスト 年齢２１から５５歳までの男性１６名，女性１４名、計
３０名からなる被検者の上腕屈側部に、クローズドパッ
チテストを実施した。試料として試験例１の試料Ａを用
いた。 判定の基準 −：全く無反応，±：軽微な紅斑，＋：明
らかな紅斑，＋＋：紅斑及び腫脹、丘疹 その結果、全被検者において、−（全く無反応）であ
り、刺激反応及びアレルギー反応を惹起する可能性は非
常に少なく、本発明のコラーゲン合成促進剤の安全性が
高く、皮膚化粧料に配合し得るものであることは明らか
となった。Test Example 3. Patch test A closed patch test was performed on the upper arm flexion region of 30 subjects, 16 males and 14 females aged 21 to 55 years old in total. The sample A of Test Example 1 was used as the sample. Criteria for judgment −: No reaction, ±: Minor erythema, +: Clear erythema, ++: Erythema and swelling, papules As a result, in all subjects, − (no reaction), irritation reaction and allergy. It was revealed that the possibility of causing a reaction is very low, the collagen synthesis promoter of the present invention is highly safe, and that it can be incorporated into a skin cosmetic.
【００２６】実施例１ 〈化粧水〉 グリセリン ５％ プロピレングリコール ４％ オレイルアルコール ０．１％ ポリオキシエチレンソルビタンモノラウリン酸エステル １．５％ ポリオキシエチレンラウリルエーテル ０．５％ エタノール １０％ 試験例１の試料Ａ １０％ 香料，染料，防腐剤，紫外線吸収剤 適量 精製水 ６８．９％Example 1 <Lotion> Glycerin 5% Propylene glycol 4% Oleyl alcohol 0.1% Polyoxyethylene sorbitan monolaurate 1.5% Polyoxyethylene lauryl ether 0.5% Ethanol 10% Test Example 1 Sample A 10% Fragrance, dye, preservative, UV absorber Appropriate amount Purified water 68.9%
【００２７】実施例２ 〈クリーム〉 ステアリルアルコール ７％ ステアリン酸 ２％ 還元ラノリン ５％ スクワラン ６％ オクチドデカノール ３％ ポリオキシエチレンセチルエーテル ２％ 親油型モノステアリン酸グリセリン ５％ プロピレングリコール ５％ 試験例１の試料Ｂ １０％ 香料，防腐剤，酸化防止剤 適量 精製水 ５８％Example 2 <Cream> Stearyl alcohol 7% Stearic acid 2% Reduced lanolin 5% Squalane 6% Octidodecanol 3% Polyoxyethylene cetyl ether 2% Lipophilic glyceryl monostearate 5% Propylene glycol 5% Test Sample B of Example 1 10% Fragrance, preservative, antioxidant Proper amount Purified water 58%
【００２８】実施例３ 〈乳液〉 ステアリン酸 ０．２％ セタノール １．５％ ワセリン ３％ ラノリンアルコール ２％ 流動パラフィン １０％ ポリオキシエチレンモノオレイン酸エステル ２％ グリセリン ３％ プロピレングリコール ５％ トリエタノールアミン １％ 試験例１の試料Ｃ １５％ 香料，防腐剤，酸化防止剤 適量 精製水 ５７．３％Example 3 Emulsion Stearic acid 0.2% Cetanol 1.5% Vaseline 3% Lanolin alcohol 2% Liquid paraffin 10% Polyoxyethylene monooleate 2% Glycerin 3% Propylene glycol 5% Triethanolamine 1% Sample C of Test Example 1 15% Fragrance, preservative, antioxidant Proper amount Purified water 57.3%
【００２９】実施例４ 〈パック〉 ポリビニルアルコール １５％ カルボキシメチルセルロースナトリウム ５％ プロピレングリコール ３％ エタノール １０％ 試験例１の試料Ｄ ５％ 香料，防腐剤，酸化剤 適量 精製水 ６２％Example 4 <Pack> Polyvinyl alcohol 15% Sodium carboxymethylcellulose 5% Propylene glycol 3% Ethanol 10% Sample D of Test Example 1 5% Fragrance, preservative, oxidizer Suitable amount Purified water 62%
【００３０】本発明の実施態様ならびに目的生成物を挙
げれば以下のとおりである。 （１）胎盤由来の成分を含有することを特徴とするコラ
ーゲン合成促進剤。 （２）胎盤がヒト，ウシ，ヤギ，ヒツジ，ブタの胎盤よ
り選ばれる１種又は２種以上である前記（１）記載のコ
ラーゲン合成促進剤。 （３）胎盤がヒト，ウシ，ブタの胎盤より選ばれる１種
又は２種以上である前記（１）記載のコラーゲン合成促
進剤。 （４）胎盤がヒトの胎盤である前記（１）記載のコラー
ゲン合成促進剤。 （５）胎盤がウシの胎盤である前記（１）記載のコラー
ゲン合成促進剤。 （６）胎盤がブタの胎盤である前記（１）記載のコラー
ゲン合成促進剤。The embodiments of the present invention and the desired products are as follows. (1) A collagen synthesis promoter comprising a placenta-derived component. (2) The collagen synthesis promoter according to (1), wherein the placenta is one or more selected from human, bovine, goat, sheep, and porcine placenta. (3) The collagen synthesis promoter according to (1), wherein the placenta is one or more selected from human, bovine, and porcine placenta. (4) The collagen synthesis promoter according to (1) above, wherein the placenta is a human placenta. (5) The collagen synthesis promoter according to (1) above, wherein the placenta is a bovine placenta. (6) The collagen synthesis promoter according to (1) above, wherein the placenta is a pig placenta.
【００３１】（７）胎盤由来の成分が、コラーゲン合成
促進作用成分を豊富に含有する胎盤の分画成分である前
記（１）記載のコラーゲン合成促進剤。 （８）胎盤の分画成分が、分子量１万以下の画分である
前記（７）記載のコラーゲン合成促進剤。 （９）胎盤由来の成分が、酸・アルコール処理によって
得られる前記（１）、（７）記載のコラーゲン合成促進
剤。 （１０）胎盤の分画成分が、酸・アルコール処理によっ
て得られる前記（７）記載のコラーゲン合成促進剤。 （１１）分子量１万以下の画分が酸・アルコール処理に
よって得られる前記（８）記載のコラーゲン合成促進
剤。 （１２）酸・アルコール処理がｐＨ１〜６の条件下で不
溶物を除去する処理である前記（９）〜（１１）記載の
コラーゲン合成促進剤。 （１３）酸・アルコール処理がｐＨ２〜５．５の条件下
で不溶物を除去する処理である前記（９）〜（１１）記
載のコラーゲン合成促進剤。 （１４）酸・アルコール処理がアルコール濃度１０〜５
０％（Ｖ／Ｖ）の条件下で不溶物を除去する処理である
前記（９）〜（１１）記載のコラーゲン合成促進剤。 （１５）酸・アルコール処理がアルコール濃度２０〜４
０％（Ｖ／Ｖ）の条件下で不溶物を除去する処理である
前記（９）〜（１１）記載のコラーゲン合成促進剤。(7) The collagen synthesis promoter according to (1) above, wherein the placenta-derived component is a fractionated component of the placenta, which is rich in collagen synthesis promoting components. (8) The collagen synthesis promoter according to (7) above, wherein the fractionated component of placenta is a fraction having a molecular weight of 10,000 or less. (9) The collagen synthesis promoter according to the above (1) or (7), wherein the placenta-derived component is obtained by acid / alcohol treatment. (10) The collagen synthesis promoter according to (7) above, wherein the fractionated component of the placenta is obtained by acid / alcohol treatment. (11) The collagen synthesis promoter according to the above (8), wherein a fraction having a molecular weight of 10,000 or less is obtained by treatment with an acid / alcohol. (12) The collagen synthesis promoter according to the above (9) to (11), wherein the acid / alcohol treatment is a treatment for removing insoluble matter under conditions of pH 1 to 6. (13) The collagen synthesis promoter according to the above (9) to (11), wherein the acid / alcohol treatment is a treatment for removing insoluble matter under the condition of pH 2 to 5.5. (14) Acid / alcohol treatment causes alcohol concentration of 10-5
The collagen synthesis promoter according to the above (9) to (11), which is a treatment for removing insolubles under the condition of 0% (V / V). (15) Acid / alcohol treatment causes alcohol concentration of 20-4
The collagen synthesis promoter according to the above (9) to (11), which is a treatment for removing insolubles under the condition of 0% (V / V).
【００３２】（１６）酸・アルコール処理がｐＨ１〜
６，アルコール濃度１０〜５０％（Ｖ／Ｖ）の条件下で
不溶物を除去する処理である前記（９）〜（１１）記載
のコラーゲン合成促進剤。 （１７）酸・アルコール処理がｐＨ２〜５．５，アルコ
ール濃度１０〜５０％（Ｖ／Ｖ）の条件下で不溶物を除
去する処理である前記（９）〜（１１）記載のコラーゲ
ン合成促進剤。 （１８）酸・アルコール処理がｐＨ１〜６，アルコール
濃度２０〜４０％（Ｖ／Ｖ）の条件下で不溶物を除去す
る処理である前記（９）〜（１１）記載のコラーゲン合
成促進剤。 （１９）酸・アルコール処理がｐＨ２〜５．５，アルコ
ール濃度２０〜４０％（Ｖ／Ｖ）の条件下で不溶物を除
去する処理である前記（９）〜（１１）記載のコラーゲ
ン合成促進剤。(16) Acid / alcohol treatment has a pH of 1 to
6, The collagen synthesis promoter according to the above (9) to (11), which is a treatment for removing insoluble matter under the condition of an alcohol concentration of 10 to 50% (V / V). (17) The collagen synthesis promotion according to the above (9) to (11), wherein the acid / alcohol treatment is a treatment for removing insoluble matter under conditions of pH 2 to 5.5 and alcohol concentration 10 to 50% (V / V). Agent. (18) The collagen synthesis promoter according to the above (9) to (11), wherein the acid / alcohol treatment is a treatment for removing insoluble matter under the conditions of pH 1-6 and alcohol concentration 20-40% (V / V). (19) Acceleration of collagen synthesis according to the above (9) to (11), wherein the acid / alcohol treatment is a treatment for removing insoluble matter under conditions of pH 2 to 5.5 and alcohol concentration 20 to 40% (V / V). Agent.
【００３３】（２０）アルコールがメタノール，エタノ
ール，イソプロパノール，ｎ−ブタノールより選ばれる
１種又は２種以上である前記（９）〜（１９）記載のコ
ラーゲン合成促進剤。 （２１）アルコールがメタノール，エタノール，イソプ
ロパノールより選ばれる１種又は２種以上である前記
（９）〜（１９）記載のコラーゲン合成促進剤。 （２２）アルコールがメタノールである前記（９）〜
（１９）記載のコラーゲン合成促進剤。 （２３）アルコールがエタノールである前記（９）〜
（１９）記載のコラーゲン合成促進剤。 （２４）アルコールがイソプロパノールである前記
（９）〜（１９）記載のコラーゲン合成促進剤。 （２５）酸が塩酸，酢酸，乳酸，硫酸，クエン酸，リン
酸より選ばれる１種又は２種以上である前記（９）〜
（１９）記載のコラーゲン合成促進剤。 （２６）酸が塩酸である前記（９）〜（１９）記載のコ
ラーゲン合成促進剤。 （２７）酸が乳酸である前記（９）〜（１９）記載のコ
ラーゲン合成促進剤。 （２８）酸がクエン酸である前記（９）〜（１９）記載
のコラーゲン合成促進剤。 （２９）前記（１）〜（２８）記載のコラーゲン合成促
進剤の製造法。 （３０）前記（１）〜（２８）記載のコラーゲン合成促
進剤を含有することを特徴とする皮膚化粧料。 （３１）前記（３０）記載の皮膚化粧料の製造法。(20) The collagen synthesis promoter according to the above (9) to (19), wherein the alcohol is one or more selected from methanol, ethanol, isopropanol and n-butanol. (21) The collagen synthesis promoter according to the above (9) to (19), wherein the alcohol is one kind or two or more kinds selected from methanol, ethanol and isopropanol. (22) The above (9), wherein the alcohol is methanol.
The collagen synthesis promoter according to (19). (23) The above (9), wherein the alcohol is ethanol.
The collagen synthesis promoter according to (19). (24) The collagen synthesis promoter according to the above (9) to (19), wherein the alcohol is isopropanol. (25) The above-mentioned (9) to which the acid is one or more selected from hydrochloric acid, acetic acid, lactic acid, sulfuric acid, citric acid and phosphoric acid.
The collagen synthesis promoter according to (19). (26) The collagen synthesis promoter according to the above (9) to (19), wherein the acid is hydrochloric acid. (27) The collagen synthesis promoter according to the above (9) to (19), wherein the acid is lactic acid. (28) The collagen synthesis promoter according to the above (9) to (19), wherein the acid is citric acid. (29) The method for producing the collagen synthesis promoter according to the above (1) to (28). (30) A skin cosmetic containing the collagen synthesis promoter according to any one of (1) to (28). (31) The method for producing a skin cosmetic according to (30) above.
【００３４】[0034]
【発明の効果】以上詳述した如く本願発明のコラーゲン
合成促進剤は優れたコラーゲン合成促進作用を有し、こ
の合成促進剤が添加された皮膚化粧料は、皮膚機能を促
進し、秦の皺を防止し、きめ細やかな、しっとりした皮
膚を与える効果を有する。従って本発明の産業上の意義
は非常に大きい。Industrial Applicability As described in detail above, the collagen synthesis promoter of the present invention has an excellent collagen synthesis promoting action, and the skin cosmetics to which this synthesis promoter is added promotes the skin function and causes the wrinkle of the Qin. And has the effect of giving a delicate, moist skin. Therefore, the industrial significance of the present invention is very great.
Claims (5)
するコラーゲン合成促進剤。1. A collagen synthesis promoter comprising a placenta-derived component.
の胎盤より選ばれる１種又は２種以上である請求項１記
載のコラーゲン合成促進剤。2. The collagen synthesis promoter according to claim 1, wherein the placenta is one or more selected from human, bovine, goat, sheep and porcine placenta.
進剤を含有することを特徴とする皮膚化粧料。3. A skin cosmetic comprising the collagen synthesis promoter according to claim 1 or 2.
て得られる分画物である請求項１記載のコラーゲン合成
促進剤の製造法。4. The method for producing a collagen synthesis promoter according to claim 1, wherein the placenta component is a fraction obtained by acid / alcohol treatment.
コール濃度１０〜５０％（Ｖ／Ｖ）の条件下で不溶物を
除去する処理である請求項４記載のコラーゲン合成促進
剤の製造法。5. The method for producing a collagen synthesis promoter according to claim 4, wherein the acid / alcohol treatment is a treatment for removing insoluble matter under conditions of pH 1-6 and alcohol concentration 10-50% (V / V).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP7062025A JPH08231370A (en) | 1995-02-23 | 1995-02-23 | Skin cosmetic |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP7062025A JPH08231370A (en) | 1995-02-23 | 1995-02-23 | Skin cosmetic |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH08231370A true JPH08231370A (en) | 1996-09-10 |
Family
ID=13188228
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP7062025A Pending JPH08231370A (en) | 1995-02-23 | 1995-02-23 | Skin cosmetic |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH08231370A (en) |
Cited By (124)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001072567A (en) * | 1999-09-07 | 2001-03-21 | Sunstar Inc | Skin cosmetic |
| JP2002097113A (en) * | 2000-09-22 | 2002-04-02 | Japan Natural Laboratory Co Ltd | Pack fee |
| JP2004520305A (en) * | 2000-12-20 | 2004-07-08 | エル・ジー ハウスホールド アンド ヘルスケア リミティッド | Composition for prevention and reduction of skin wrinkles |
| EP2153814A1 (en) | 2008-08-05 | 2010-02-17 | Isdin S.A. | Use of compositions comprising urea |
| EP2153815A1 (en) | 2008-08-05 | 2010-02-17 | Isdin S.A. | Use of urea containing compositions |
| JP2010143885A (en) * | 2008-12-22 | 2010-07-01 | Asahi Breweries Ltd | Lactobacillus and food and drink preparations or cosmetic using the same |
| JP2011177156A (en) * | 2010-03-04 | 2011-09-15 | Shigeta Hakko Kagaku Kenkyusho:Kk | Beverage containing rosemary-fermented extract and presenting collagen-increasing effect |
| KR20130083771A (en) | 2012-01-13 | 2013-07-23 | 주식회사 엘지생활건강 | Composition for improving skin wrinkle and enhancing elasticity |
| WO2014092325A1 (en) | 2012-12-13 | 2014-06-19 | 한국한의학연구원 | Skin-moisturising or wrinkle-improving external composition and cosmetic composition |
| KR20150019681A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant and anti-imflamation |
| KR20150019580A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019624A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019552A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant and anti-imflamation |
| KR20150019577A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019581A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019612A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019671A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019636A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019553A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019574A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019583A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019546A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, anti-imflamation, and skin whitening |
| KR20150019550A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle and antioxidant |
| KR20150019622A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019601A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, and anti-imflamation |
| KR20150019579A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019609A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019603A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019575A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019613A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019582A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019607A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019576A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019578A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019626A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019608A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019635A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant and anti-imflamation |
| KR20150019674A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019629A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019611A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019677A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019573A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019625A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019600A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019630A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019604A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019672A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, and skin whitening |
| KR20150019606A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019551A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019599A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150057759A (en) | 2013-11-20 | 2015-05-28 | 주식회사 엘지생활건강 | Cosmetic composition containing Oriental Herb Fragrance Active Component Limonene for Skin Benefit Ingredient |
| KR20150057767A (en) | 2013-11-20 | 2015-05-28 | 주식회사 엘지생활건강 | Cosmetic composition containing Oriental Herb Fragrance Active Component 8-heptadecene for Skin Benefit Ingredient |
| KR20150057760A (en) | 2013-11-20 | 2015-05-28 | 주식회사 엘지생활건강 | Cosmetic composition containing Oriental Herb Fragrance Active Component Terpinolene for Skin Benefit Ingredient |
| KR20150057762A (en) | 2013-11-20 | 2015-05-28 | 주식회사 엘지생활건강 | Cosmetic composition containing Oriental Herb Fragrance Active Component Estragole for Skin Benefit Ingredient |
| KR20150057758A (en) | 2013-11-20 | 2015-05-28 | 주식회사 엘지생활건강 | Cosmetic composition containing Oriental Herb Fragrance Active Component Alpha-Terpinene for Skin Benefit Ingredient |
| KR20150057906A (en) | 2013-11-18 | 2015-05-28 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, anti-inflammation, or skin whitening |
| KR20150057761A (en) | 2013-11-20 | 2015-05-28 | 주식회사 엘지생활건강 | Cosmetic composition containing Oriental Herb Fragrance Active Component alpha-fenchone for Skin Benefit Ingredient |
| KR20150057763A (en) | 2013-11-20 | 2015-05-28 | 주식회사 엘지생활건강 | Cosmetic composition containing Oriental Herb Fragrance Active Component Tridecane for Skin Benefit Ingredient |
| KR20150057757A (en) | 2013-11-20 | 2015-05-28 | 주식회사 엘지생활건강 | Cosmetic composition containing Oriental Herb Fragrance Active Component Sabinene for Skin Benefit Ingredient |
| KR20150059551A (en) | 2013-11-22 | 2015-06-01 | 주식회사 엘지생활건강 | Composition for improving skin conditions comprising panax ginseng sprout extract or fraction thereof and method for improving skin conditions using the same |
| KR20150087138A (en) | 2014-01-21 | 2015-07-29 | 주식회사 엘지생활건강 | Composition for improving skin |
| KR20150087140A (en) | 2014-01-21 | 2015-07-29 | 주식회사 엘지생활건강 | Composition for improving skin |
| KR20150087144A (en) | 2014-01-21 | 2015-07-29 | 주식회사 엘지생활건강 | Composition for improving skin |
| KR20150087149A (en) | 2014-01-21 | 2015-07-29 | 주식회사 엘지생활건강 | Composition for improving skin |
| KR20150113632A (en) | 2014-03-31 | 2015-10-08 | 주식회사 엘지생활건강 | Composition for improving skin conditions and method for improving skin conditions using the same |
| KR20160003910A (en) | 2014-07-01 | 2016-01-12 | 주식회사 엘지생활건강 | Cosmetic composition for enhancing skin elasticity or improving skin wrinkle containing herb extracts |
| KR20160003915A (en) | 2014-07-01 | 2016-01-12 | 주식회사 엘지생활건강 | Cosmetic composition for enhancing skin elasticity or improving skin wrinkle containing herb extracts |
| KR20160003918A (en) | 2014-07-01 | 2016-01-12 | 주식회사 엘지생활건강 | Cosmetic composition for enhancing skin elasticity or improving skin wrinkle containing herb extracts |
| KR20160009738A (en) | 2014-07-16 | 2016-01-27 | 주식회사 엘지생활건강 | Cosmetic compositions for improving skin wrinkle |
| KR20160019032A (en) | 2014-08-08 | 2016-02-18 | 주식회사 엘지생활건강 | Composition for preventing or improving skin anti-aging and anti-wrinkle |
| KR20160039762A (en) | 2014-10-01 | 2016-04-12 | 주식회사 엘지생활건강 | Composition for promoting collagen synthesis and use thereof |
| US9321821B2 (en) | 2013-11-14 | 2016-04-26 | Lg Household & Health Care Ltd. | Cosmetic composition for improving skin conditions comprising fusion protein |
| KR101665321B1 (en) | 2016-04-27 | 2016-10-12 | (주)네오팜 | Compositions for anti-aging |
| KR20160126771A (en) | 2015-04-24 | 2016-11-02 | 주식회사 참 존 | Composition for reducing skin wrinkle and for promoting recovery of iskin injury comprising extracts of Orostachys japonicus and Saururus chinensis |
| KR101672841B1 (en) | 2015-06-26 | 2016-11-04 | 주식회사 엘지생활건강 | Composition for improving skin |
| KR20160128770A (en) | 2015-04-29 | 2016-11-08 | 주식회사 엘지생활건강 | Composition for improving skin |
| KR20160128769A (en) | 2015-04-29 | 2016-11-08 | 주식회사 엘지생활건강 | Composition for improving skin |
| KR20160128765A (en) | 2015-04-29 | 2016-11-08 | 주식회사 엘지생활건강 | Composition for improving skin |
| KR20160128764A (en) | 2015-04-29 | 2016-11-08 | 주식회사 엘지생활건강 | Composition for improving skin |
| KR20160128766A (en) | 2015-04-29 | 2016-11-08 | 주식회사 엘지생활건강 | Composition for improving skin |
| KR20160128768A (en) | 2015-04-29 | 2016-11-08 | 주식회사 엘지생활건강 | Composition for improving skin |
| KR20170001314A (en) | 2015-06-26 | 2017-01-04 | 주식회사 엘지생활건강 | Composition for improving skin |
| KR20170001313A (en) | 2015-06-26 | 2017-01-04 | 주식회사 엘지생활건강 | Composition for improving skin |
| KR20170025370A (en) | 2015-08-28 | 2017-03-08 | 주식회사 엘지생활건강 | Composition for improving skin |
| KR20170025371A (en) | 2015-08-28 | 2017-03-08 | 주식회사 엘지생활건강 | Composition for improving skin |
| KR20170025351A (en) | 2015-08-28 | 2017-03-08 | 주식회사 엘지생활건강 | Composition for improving skin |
| KR20170025373A (en) | 2015-08-28 | 2017-03-08 | 주식회사 엘지생활건강 | Composition for improving skin |
| KR20170025363A (en) | 2015-08-28 | 2017-03-08 | 주식회사 엘지생활건강 | Composition for improving skin |
| KR20170025360A (en) | 2015-08-28 | 2017-03-08 | 주식회사 엘지생활건강 | Composition for improving skin |
| KR20170025352A (en) | 2015-08-28 | 2017-03-08 | 주식회사 엘지생활건강 | Composition for improving skin |
| KR20170025368A (en) | 2015-08-28 | 2017-03-08 | 주식회사 엘지생활건강 | Composition for improving skin |
| KR20170025375A (en) | 2015-08-28 | 2017-03-08 | 주식회사 엘지생활건강 | Composition for improving skin |
| KR20170025355A (en) | 2015-08-28 | 2017-03-08 | 주식회사 엘지생활건강 | Composition for improving skin |
| KR20170035659A (en) | 2015-09-23 | 2017-03-31 | 주식회사 엘지생활건강 | Composition for improving skin comprising perivine as active ingredient |
| KR20170035658A (en) | 2015-09-23 | 2017-03-31 | 주식회사 엘지생활건강 | Composition for improving skin comprising cryptochlorogenic acid as active ingredient |
| KR20170035661A (en) | 2015-09-23 | 2017-03-31 | 주식회사 엘지생활건강 | Composition for improving skin comprising n-Methylcytisine as active ingredient |
| KR20180060609A (en) | 2016-11-29 | 2018-06-07 | 주식회사 엘지생활건강 | Composition for improving skin |
| KR20180060607A (en) | 2016-11-29 | 2018-06-07 | 주식회사 엘지생활건강 | Composition for improving skin |
| KR20180060610A (en) | 2016-11-29 | 2018-06-07 | 주식회사 엘지생활건강 | Composition for improving skin |
| KR20180060611A (en) | 2016-11-29 | 2018-06-07 | 주식회사 엘지생활건강 | Composition for improving skin |
| KR20180060608A (en) | 2016-11-29 | 2018-06-07 | 주식회사 엘지생활건강 | Composition for improving skin |
| KR20180072381A (en) | 2016-12-21 | 2018-06-29 | 주식회사 엘지생활건강 | Composition for improving skin condition comprising extract of Pisum sativum var. arvense (L.) Poir. |
| KR20180072387A (en) | 2016-12-21 | 2018-06-29 | 주식회사 엘지생활건강 | Composition for improving skin conditions comprising an extract of Aerides japonicum |
| KR20180072379A (en) | 2016-12-21 | 2018-06-29 | 주식회사 엘지생활건강 | Composition for improving skin condition comprising extract of lily bulblet |
| WO2018230751A1 (en) | 2017-06-14 | 2018-12-20 | 주식회사 바이오솔루션 | Cosmetic composition for wrinkle reduction or anti-inflammation, containing substance p |
| KR20190011853A (en) | 2017-07-25 | 2019-02-08 | 한국해양과학기술원 | New compounds produced by a marine microorganism and composition for wrinkle improvement, elasticity improvement and whitening effect of skin |
| KR20190068502A (en) | 2019-06-05 | 2019-06-18 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20190084222A (en) | 2019-07-03 | 2019-07-16 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20190086642A (en) | 2019-07-11 | 2019-07-23 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20190087371A (en) | 2019-07-16 | 2019-07-24 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20190094325A (en) | 2019-08-02 | 2019-08-13 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20190094326A (en) | 2019-08-02 | 2019-08-13 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20190096882A (en) | 2019-08-02 | 2019-08-20 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20190098115A (en) | 2019-08-09 | 2019-08-21 | 주식회사 엘지생활건강 | Cosmetic composition containing Oriental Herb Fragrance Active Component Tridecane for Skin Benefit Ingredient |
| KR20190117445A (en) | 2019-10-07 | 2019-10-16 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20190122614A (en) | 2019-10-21 | 2019-10-30 | 주식회사 엘지생활건강 | Cosmetic composition containing Oriental Herb Fragrance Active Component Terpinolene for Skin Benefit Ingredient |
| KR20190130531A (en) | 2019-11-12 | 2019-11-22 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| WO2019225891A1 (en) | 2018-05-24 | 2019-11-28 | 주식회사 파이토코퍼레이션 | Skin anti-aging composition containing irilin b |
| KR20190135444A (en) | 2019-11-26 | 2019-12-06 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20200011516A (en) | 2020-01-21 | 2020-02-03 | 주식회사 엘지생활건강 | Cosmetic composition containing Oriental Herb Fragrance Active Component Sabinene for Skin Benefit Ingredient |
| KR20200023339A (en) | 2020-02-24 | 2020-03-04 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20200080498A (en) | 2018-12-27 | 2020-07-07 | 박성율 | Cosmetic composition for enhancing skin whitening comprising lindenenol and Rehmanniae Radix extract |
| KR20210027182A (en) | 2019-08-30 | 2021-03-10 | 주식회사 엘지생활건강 | A composition comprising extract of Lilium hansonii |
| KR102575303B1 (en) | 2022-10-06 | 2023-09-06 | 양지혜 | Composition for Improving Collagen Synthesis Comprising Plant Complex Extracts as Active Ingredients |
-
1995
- 1995-02-23 JP JP7062025A patent/JPH08231370A/en active Pending
Cited By (142)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001072567A (en) * | 1999-09-07 | 2001-03-21 | Sunstar Inc | Skin cosmetic |
| JP2002097113A (en) * | 2000-09-22 | 2002-04-02 | Japan Natural Laboratory Co Ltd | Pack fee |
| JP2004520305A (en) * | 2000-12-20 | 2004-07-08 | エル・ジー ハウスホールド アンド ヘルスケア リミティッド | Composition for prevention and reduction of skin wrinkles |
| EP2153814A1 (en) | 2008-08-05 | 2010-02-17 | Isdin S.A. | Use of compositions comprising urea |
| EP2153815A1 (en) | 2008-08-05 | 2010-02-17 | Isdin S.A. | Use of urea containing compositions |
| JP2010143885A (en) * | 2008-12-22 | 2010-07-01 | Asahi Breweries Ltd | Lactobacillus and food and drink preparations or cosmetic using the same |
| JP2011177156A (en) * | 2010-03-04 | 2011-09-15 | Shigeta Hakko Kagaku Kenkyusho:Kk | Beverage containing rosemary-fermented extract and presenting collagen-increasing effect |
| KR20130083771A (en) | 2012-01-13 | 2013-07-23 | 주식회사 엘지생활건강 | Composition for improving skin wrinkle and enhancing elasticity |
| KR20130083777A (en) | 2012-01-13 | 2013-07-23 | 주식회사 엘지생활건강 | Composition for improving skin wrinkle and enhancing elasticity |
| KR20130083783A (en) | 2012-01-13 | 2013-07-23 | 주식회사 엘지생활건강 | Composition for improving skin wrinkle and enhancing elasticity |
| KR20130083782A (en) | 2012-01-13 | 2013-07-23 | 주식회사 엘지생활건강 | Composition for improving skin wrinkle and enhancing elasticity |
| WO2014092325A1 (en) | 2012-12-13 | 2014-06-19 | 한국한의학연구원 | Skin-moisturising or wrinkle-improving external composition and cosmetic composition |
| US9839594B2 (en) | 2012-12-13 | 2017-12-12 | Korea Institute Of Oriental Medicine | Skin-moisturising or wrinkle-improving external composition and cosmetic composition |
| KR20150019575A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019635A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant and anti-imflamation |
| KR20150019624A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019552A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant and anti-imflamation |
| KR20150019577A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019581A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019612A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019671A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019636A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019553A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019574A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019583A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019546A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, anti-imflamation, and skin whitening |
| KR20150019550A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle and antioxidant |
| KR20150019622A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019601A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, and anti-imflamation |
| KR20150019579A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019609A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019603A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019681A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant and anti-imflamation |
| KR20150019613A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019582A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019607A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019576A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019578A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019626A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019608A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019580A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019674A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019629A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019611A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019677A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019573A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019625A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019600A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019630A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019604A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019672A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, and skin whitening |
| KR20150019606A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019551A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20150019599A (en) | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| US9963484B2 (en) | 2013-11-14 | 2018-05-08 | Lg Household & Health Care Ltd. | Polynucleotide encoding a fusion protein for improving skin conditions |
| US9321821B2 (en) | 2013-11-14 | 2016-04-26 | Lg Household & Health Care Ltd. | Cosmetic composition for improving skin conditions comprising fusion protein |
| KR20150057902A (en) | 2013-11-18 | 2015-05-28 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, anti-inflammation, or skin whitening |
| KR20150057906A (en) | 2013-11-18 | 2015-05-28 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, anti-inflammation, or skin whitening |
| KR20150057896A (en) | 2013-11-18 | 2015-05-28 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, anti-imflamation, or skin whitening |
| KR20150057898A (en) | 2013-11-18 | 2015-05-28 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, anti-imflamation, and skin whitening |
| KR20150057900A (en) | 2013-11-18 | 2015-05-28 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, anti-imflamation, or skin whitening |
| KR20150057903A (en) | 2013-11-18 | 2015-05-28 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, anti-inflammation, or skin whitening |
| KR20210005820A (en) | 2013-11-18 | 2021-01-15 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, anti-inflammation, or skin whitening |
| KR20150057907A (en) | 2013-11-18 | 2015-05-28 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, anti-imflammation, or skin whitening |
| KR20150057908A (en) | 2013-11-18 | 2015-05-28 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, anti-imflammation, or skin whitening |
| KR20150057905A (en) | 2013-11-18 | 2015-05-28 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, anti-inflammation, or skin whitening |
| KR20150057901A (en) | 2013-11-18 | 2015-05-28 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, anti-inflammation, or skin whitening |
| KR20150057757A (en) | 2013-11-20 | 2015-05-28 | 주식회사 엘지생활건강 | Cosmetic composition containing Oriental Herb Fragrance Active Component Sabinene for Skin Benefit Ingredient |
| KR20150057763A (en) | 2013-11-20 | 2015-05-28 | 주식회사 엘지생활건강 | Cosmetic composition containing Oriental Herb Fragrance Active Component Tridecane for Skin Benefit Ingredient |
| KR20150057761A (en) | 2013-11-20 | 2015-05-28 | 주식회사 엘지생활건강 | Cosmetic composition containing Oriental Herb Fragrance Active Component alpha-fenchone for Skin Benefit Ingredient |
| KR20150057758A (en) | 2013-11-20 | 2015-05-28 | 주식회사 엘지생활건강 | Cosmetic composition containing Oriental Herb Fragrance Active Component Alpha-Terpinene for Skin Benefit Ingredient |
| KR20150057762A (en) | 2013-11-20 | 2015-05-28 | 주식회사 엘지생활건강 | Cosmetic composition containing Oriental Herb Fragrance Active Component Estragole for Skin Benefit Ingredient |
| KR20150057759A (en) | 2013-11-20 | 2015-05-28 | 주식회사 엘지생활건강 | Cosmetic composition containing Oriental Herb Fragrance Active Component Limonene for Skin Benefit Ingredient |
| KR20150057767A (en) | 2013-11-20 | 2015-05-28 | 주식회사 엘지생활건강 | Cosmetic composition containing Oriental Herb Fragrance Active Component 8-heptadecene for Skin Benefit Ingredient |
| KR20150057760A (en) | 2013-11-20 | 2015-05-28 | 주식회사 엘지생활건강 | Cosmetic composition containing Oriental Herb Fragrance Active Component Terpinolene for Skin Benefit Ingredient |
| KR20150059551A (en) | 2013-11-22 | 2015-06-01 | 주식회사 엘지생활건강 | Composition for improving skin conditions comprising panax ginseng sprout extract or fraction thereof and method for improving skin conditions using the same |
| KR20150087149A (en) | 2014-01-21 | 2015-07-29 | 주식회사 엘지생활건강 | Composition for improving skin |
| KR20150087144A (en) | 2014-01-21 | 2015-07-29 | 주식회사 엘지생활건강 | Composition for improving skin |
| KR20150087140A (en) | 2014-01-21 | 2015-07-29 | 주식회사 엘지생활건강 | Composition for improving skin |
| KR20150087138A (en) | 2014-01-21 | 2015-07-29 | 주식회사 엘지생활건강 | Composition for improving skin |
| KR20210151024A (en) | 2014-01-21 | 2021-12-13 | 주식회사 엘지생활건강 | Composition for improving skin |
| KR20160114018A (en) | 2014-01-21 | 2016-10-04 | 주식회사 엘지생활건강 | Composition for improving skin |
| KR20150113632A (en) | 2014-03-31 | 2015-10-08 | 주식회사 엘지생활건강 | Composition for improving skin conditions and method for improving skin conditions using the same |
| KR20160003910A (en) | 2014-07-01 | 2016-01-12 | 주식회사 엘지생활건강 | Cosmetic composition for enhancing skin elasticity or improving skin wrinkle containing herb extracts |
| KR20160003915A (en) | 2014-07-01 | 2016-01-12 | 주식회사 엘지생활건강 | Cosmetic composition for enhancing skin elasticity or improving skin wrinkle containing herb extracts |
| KR20160003918A (en) | 2014-07-01 | 2016-01-12 | 주식회사 엘지생활건강 | Cosmetic composition for enhancing skin elasticity or improving skin wrinkle containing herb extracts |
| KR20160009738A (en) | 2014-07-16 | 2016-01-27 | 주식회사 엘지생활건강 | Cosmetic compositions for improving skin wrinkle |
| KR20160019032A (en) | 2014-08-08 | 2016-02-18 | 주식회사 엘지생활건강 | Composition for preventing or improving skin anti-aging and anti-wrinkle |
| KR20160039762A (en) | 2014-10-01 | 2016-04-12 | 주식회사 엘지생활건강 | Composition for promoting collagen synthesis and use thereof |
| KR20160126771A (en) | 2015-04-24 | 2016-11-02 | 주식회사 참 존 | Composition for reducing skin wrinkle and for promoting recovery of iskin injury comprising extracts of Orostachys japonicus and Saururus chinensis |
| KR20160128769A (en) | 2015-04-29 | 2016-11-08 | 주식회사 엘지생활건강 | Composition for improving skin |
| KR20160128764A (en) | 2015-04-29 | 2016-11-08 | 주식회사 엘지생활건강 | Composition for improving skin |
| KR20160128766A (en) | 2015-04-29 | 2016-11-08 | 주식회사 엘지생활건강 | Composition for improving skin |
| KR20160128768A (en) | 2015-04-29 | 2016-11-08 | 주식회사 엘지생활건강 | Composition for improving skin |
| KR20160128765A (en) | 2015-04-29 | 2016-11-08 | 주식회사 엘지생활건강 | Composition for improving skin |
| KR20160128770A (en) | 2015-04-29 | 2016-11-08 | 주식회사 엘지생활건강 | Composition for improving skin |
| KR20220008371A (en) | 2015-04-29 | 2022-01-20 | 주식회사 엘지생활건강 | Composition for improving skin |
| KR101672841B1 (en) | 2015-06-26 | 2016-11-04 | 주식회사 엘지생활건강 | Composition for improving skin |
| KR20170001313A (en) | 2015-06-26 | 2017-01-04 | 주식회사 엘지생활건강 | Composition for improving skin |
| KR20170001314A (en) | 2015-06-26 | 2017-01-04 | 주식회사 엘지생활건강 | Composition for improving skin |
| KR20170025375A (en) | 2015-08-28 | 2017-03-08 | 주식회사 엘지생활건강 | Composition for improving skin |
| KR20170025351A (en) | 2015-08-28 | 2017-03-08 | 주식회사 엘지생활건강 | Composition for improving skin |
| KR20170025352A (en) | 2015-08-28 | 2017-03-08 | 주식회사 엘지생활건강 | Composition for improving skin |
| KR20170025368A (en) | 2015-08-28 | 2017-03-08 | 주식회사 엘지생활건강 | Composition for improving skin |
| KR20170025363A (en) | 2015-08-28 | 2017-03-08 | 주식회사 엘지생활건강 | Composition for improving skin |
| KR20170025355A (en) | 2015-08-28 | 2017-03-08 | 주식회사 엘지생활건강 | Composition for improving skin |
| KR20170025370A (en) | 2015-08-28 | 2017-03-08 | 주식회사 엘지생활건강 | Composition for improving skin |
| KR20170025371A (en) | 2015-08-28 | 2017-03-08 | 주식회사 엘지생활건강 | Composition for improving skin |
| KR20170025360A (en) | 2015-08-28 | 2017-03-08 | 주식회사 엘지생활건강 | Composition for improving skin |
| KR20170025373A (en) | 2015-08-28 | 2017-03-08 | 주식회사 엘지생활건강 | Composition for improving skin |
| KR20170035661A (en) | 2015-09-23 | 2017-03-31 | 주식회사 엘지생활건강 | Composition for improving skin comprising n-Methylcytisine as active ingredient |
| KR20170035658A (en) | 2015-09-23 | 2017-03-31 | 주식회사 엘지생활건강 | Composition for improving skin comprising cryptochlorogenic acid as active ingredient |
| KR20170035659A (en) | 2015-09-23 | 2017-03-31 | 주식회사 엘지생활건강 | Composition for improving skin comprising perivine as active ingredient |
| KR101665321B1 (en) | 2016-04-27 | 2016-10-12 | (주)네오팜 | Compositions for anti-aging |
| KR20180060610A (en) | 2016-11-29 | 2018-06-07 | 주식회사 엘지생활건강 | Composition for improving skin |
| KR20180060608A (en) | 2016-11-29 | 2018-06-07 | 주식회사 엘지생활건강 | Composition for improving skin |
| KR20180060611A (en) | 2016-11-29 | 2018-06-07 | 주식회사 엘지생활건강 | Composition for improving skin |
| KR20180060607A (en) | 2016-11-29 | 2018-06-07 | 주식회사 엘지생활건강 | Composition for improving skin |
| KR20180060609A (en) | 2016-11-29 | 2018-06-07 | 주식회사 엘지생활건강 | Composition for improving skin |
| KR20180072381A (en) | 2016-12-21 | 2018-06-29 | 주식회사 엘지생활건강 | Composition for improving skin condition comprising extract of Pisum sativum var. arvense (L.) Poir. |
| KR20180072387A (en) | 2016-12-21 | 2018-06-29 | 주식회사 엘지생활건강 | Composition for improving skin conditions comprising an extract of Aerides japonicum |
| KR20180072379A (en) | 2016-12-21 | 2018-06-29 | 주식회사 엘지생활건강 | Composition for improving skin condition comprising extract of lily bulblet |
| WO2018230751A1 (en) | 2017-06-14 | 2018-12-20 | 주식회사 바이오솔루션 | Cosmetic composition for wrinkle reduction or anti-inflammation, containing substance p |
| KR20190011853A (en) | 2017-07-25 | 2019-02-08 | 한국해양과학기술원 | New compounds produced by a marine microorganism and composition for wrinkle improvement, elasticity improvement and whitening effect of skin |
| WO2019225891A1 (en) | 2018-05-24 | 2019-11-28 | 주식회사 파이토코퍼레이션 | Skin anti-aging composition containing irilin b |
| KR20200080498A (en) | 2018-12-27 | 2020-07-07 | 박성율 | Cosmetic composition for enhancing skin whitening comprising lindenenol and Rehmanniae Radix extract |
| KR20190068502A (en) | 2019-06-05 | 2019-06-18 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20190084222A (en) | 2019-07-03 | 2019-07-16 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20190086642A (en) | 2019-07-11 | 2019-07-23 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20190087371A (en) | 2019-07-16 | 2019-07-24 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20190094325A (en) | 2019-08-02 | 2019-08-13 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20190096882A (en) | 2019-08-02 | 2019-08-20 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20190094326A (en) | 2019-08-02 | 2019-08-13 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20190098115A (en) | 2019-08-09 | 2019-08-21 | 주식회사 엘지생활건강 | Cosmetic composition containing Oriental Herb Fragrance Active Component Tridecane for Skin Benefit Ingredient |
| KR20210027182A (en) | 2019-08-30 | 2021-03-10 | 주식회사 엘지생활건강 | A composition comprising extract of Lilium hansonii |
| KR20190117445A (en) | 2019-10-07 | 2019-10-16 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20190122614A (en) | 2019-10-21 | 2019-10-30 | 주식회사 엘지생활건강 | Cosmetic composition containing Oriental Herb Fragrance Active Component Terpinolene for Skin Benefit Ingredient |
| KR20190130531A (en) | 2019-11-12 | 2019-11-22 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20190135444A (en) | 2019-11-26 | 2019-12-06 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR20200011516A (en) | 2020-01-21 | 2020-02-03 | 주식회사 엘지생활건강 | Cosmetic composition containing Oriental Herb Fragrance Active Component Sabinene for Skin Benefit Ingredient |
| KR20200023339A (en) | 2020-02-24 | 2020-03-04 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
| KR102575303B1 (en) | 2022-10-06 | 2023-09-06 | 양지혜 | Composition for Improving Collagen Synthesis Comprising Plant Complex Extracts as Active Ingredients |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH08231370A (en) | Skin cosmetic | |
| US5322839A (en) | Protein fraction for cosmetic and dermatology care of the skin | |
| PL187989B1 (en) | Shark cartilage extracts, method of obtaining such extracts and compositions containing them | |
| US20050107302A1 (en) | Wound healing composition and method for use thereof | |
| JP2002524487A (en) | Use of a peptide for scarring, moisturizing and improving skin appearance as a cosmetic or dermatological agent during natural aging or hyperaging (sun dermatitis, contamination) | |
| CN103619415A (en) | Exopolysaccharide for the treatment and/or care of the skin, mucous membranes, hair and/or nails | |
| JP2002193738A (en) | Use of at least one extract of at least one rhododendron in a composition for treating the signs of skin aging | |
| JP3249844B2 (en) | Skin cosmetics | |
| US20190111108A1 (en) | Composition Including GDF11 and Use Thereof | |
| ES2693261T3 (en) | Use of C-glycoside derivatives as pro-desquamating active agents | |
| JP2005306831A (en) | Skin preparation | |
| JP2013095708A (en) | Medusa collagen peptide mixture | |
| JP2002534454A (en) | Use of a plant extract of Rosmarinus in a composition for treating the signs of aging skin | |
| EP2763686A1 (en) | Composition for the treatment of skin lesions | |
| KR101186130B1 (en) | Pharmaceutical or cosmetic compositions comprising nicotinic acid adenine dinucleotide phosphate and its derivatives | |
| JPH05320039A (en) | Skin-beautifying cosmetic | |
| JP3172753B2 (en) | Biological hyaluronic acid synthesis promoter | |
| JP2007262012A (en) | Hyaluronic acid production promoter, skin external preparation containing the hyaluronic acid production promoter, cosmetic, quasi drug, chapped skin ameliorating agent, and wrinkle ameliorating agent | |
| JP2533376B2 (en) | Skin cosmetics | |
| EA020417B1 (en) | Compositions for treating rosacea | |
| JP3073862B2 (en) | Hyaluronic acid production promoter | |
| JPH0383908A (en) | Skin cosmetic | |
| CN118845595B (en) | A skin whitening, rejuvenation and brightening composition and its preparation method and application | |
| JP2006265120A (en) | Collagen synthesis promoter | |
| JP2998846B2 (en) | Whitening cosmetics |